GALNAC-conjugated modified oligonucleotides as MIR-122 inhibitors with HCV antiviral activity and reduced hyperbilirubinemia side effects
By combining the miR-122-targeting compound RG6650 with DAA, the problems of resistance and poor compliance associated with high HCV mutation rates were solved, resulting in higher cure rates and shorter treatment cycles.
Patent Information
- Application Number
- CN201980044398.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-05-08
- Filing Date
- 2019-05-07
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2039-05-07
AI Technical Summary
Existing antiviral drugs have issues related to resistance to HCV's high mutation rate and poor patient compliance, leading to some HCV-infected individuals not responding to treatment or experiencing relapse.
A compound called RG6650 targeting miR-122 was developed, which inhibits miR-122 activity in a complementary manner and can be used in combination with direct-acting antiviral agents (DAAs) to shorten treatment duration and improve adherence.
It significantly reduces HCV RNA levels, achieving higher cure rates and shorter treatment times, reducing side effects, and improving patient compliance.
Smart Images

Figure BDA0002870432900000241 
Figure BDA0002870432900000251 
Figure BDA0002870432900000391
Abstract
Description
Technical Field
[0001] Provided herein are compounds and methods for modulating the activity of miR-122. Such methods include treating diseases associated with miR-122 activity, such as HCV infection. Background Art
[0002] MicroRNA (MicroRNA or microRNA), also referred to as "mature microRNA", is a small (about 18-24 nucleotides in length) non-coding RNA molecule encoded in the genome of plants and animals. In some cases, highly conserved, endogenously expressed microRNA regulates gene expression by binding to the 3'-untranslated region (3'-UTR) of a specific mRNA. More than 1000 different microRNAs have been identified in plants and animals. Some mature microRNAs appear to originate from long endogenous primary microRNA transcripts (also referred to as pri-microRNA, pri-mir, pri-miR or pri-pre-microRNA), which are typically hundreds of nucleotides in length ((Lee et al., EMBO J., 2002, 21 (17), 4663-4670).
[0003] miR-122, a microRNA abundant and specifically expressed in the liver, is a key host factor for the accumulation of hepatitis C virus (Jopling et al., Science. 2005, 309(5740): 1577-81). miR-122 interacts with HCV by binding to two closely spaced seed sequence sites in the 5' non-coding region of the HCV genome, thereby causing stabilization of the HCV genome, supporting replication and translation (Jangra et al., J Virol., 2010, 84: 6615-6625; Machlin et al., 2011). Importantly, the miR-122 binding site is completely conserved in the HCV genome of all genotypes and subtypes (Wilson et al., J. Virol., 2011, 85: 2342-2350). Inhibition of miR-122 with anti-miRs results in decreased total circulating cholesterol levels in mice and cynomolgus monkeys, as well as changes in the expression of genes involved in cholesterol homeostasis, fatty acid and lipid metabolism (Esau et al., 2006, Cell Metabolism, 3: 87-98). In untreated chronic HCV-infected subjects, mirevisin (an LNA-modified anti-miR-122 oligonucleotide) resulted in a reduction in serum HCV RNA (Janssen et al., N Engl J Med., 2013, 368: 1685-1694). A single administration of RG-101 (a hepatocyte-targeted anti-miR-122 compound) was well tolerated and resulted in a significant reduction in viral load in HCV-infected subjects (van der Ree et al., 2017, Lancet, 389(10070): 709-717).
[0004] Although current direct-acting antiviral drugs are achieving a high rate of sustained viral response, there is still an underserved population of HCV infected subjects who do not respond to current treatments or relapse after successful treatment. Resistance to antiviral therapy is a major problem associated with the high mutation rate of HCV and can be observed even with drug combinations. In addition, subjects need to take oral agents at least once a day for a long time (e.g., for Poor compliance with treatment regimens (eg, 12 weeks) can interfere with achieving high response rates. Therefore, therapeutic agents targeting conserved, mutation-resistant viral host factors such as miR-122 represent an opportunity to achieve higher and more durable cure rates. Summary of the invention
[0005] Embodiment 1. A compound having the following structure:
[0006] ,
[0007] or a pharmaceutically acceptable salt thereof.
[0008] Embodiment 2. The compound of Embodiment 1, which is a pharmaceutically acceptable salt of the structure.
[0009] Embodiment 3. The compound of Embodiment 2, which is a sodium salt having the structure.
[0010] Embodiment 4. A pharmaceutical composition comprising a compound according to any one of Embodiments 1 to 3 and a pharmaceutically acceptable diluent.
[0011] Embodiment 5. The pharmaceutical composition of embodiment 4, wherein the pharmaceutically acceptable diluent is an aqueous solution.
[0012] Embodiment 6. The pharmaceutical composition of embodiment 5, wherein the aqueous solution is a saline solution.
[0013] Embodiment 7. A pharmaceutical composition comprising a compound according to any one of embodiments 1 to 3, which is a lyophilized composition.
[0014] Embodiment 8. A pharmaceutical composition consisting essentially of a compound according to any one of Embodiments 1 to 3 in saline solution.
[0015] Embodiment 9. A method of inhibiting the activity of miR-122 in a cell, the method comprising contacting the cell with a compound according to any one of embodiments 1 to 3.
[0016] Embodiment 10. The method of embodiment 9, wherein the cell is in vivo.
[0017] Embodiment 11. The method of embodiment 9, wherein the cell is in vitro.
[0018] Embodiment 12. A method of treating HCV infection, comprising administering to an HCV infected subject at least one dose of a compound according to any one of embodiments 1 to 3 or a pharmaceutical composition according to any one of embodiments 4 to 8.
[0019] Embodiment 13. A method of treating hepatitis C virus (HCV) infection, the method comprising administering to an HCV-infected subject at least one dose of a compound as described in any one of embodiments 1 to 3 or a pharmaceutical composition as described in any one of embodiments 4 to 8 and at least one direct-acting antiviral drug (DAA) during a treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a starting dose of the compound or pharmaceutical composition is administered at the beginning of the treatment period and a terminating dose of the compound or pharmaceutical composition is administered at the end of the treatment period.
[0020] Embodiment 14. The method of embodiment 13, wherein said starting dose and said ending dose are the only doses of the compound or pharmaceutical composition administered during the treatment period.
[0021] Embodiment 15. A method of treating hepatitis C virus (HCV) infection, the method comprising administering to an HCV-infected subject at least one dose of a compound as described in any one of embodiments 1 to 3 or a pharmaceutical composition as described in any one of embodiments 4 to 8 and at least one direct-acting antiviral drug (DAA) during a treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a starting dose of the compound or pharmaceutical composition is administered at the beginning of the treatment period, and the starting dose is the only dose of the compound or pharmaceutical composition administered during the treatment period.
[0022] Embodiment 16. A method of treating hepatitis C virus (HCV) infection, the method comprising administering to an HCV-infected subject at least one dose of a compound as described in any one of embodiments 1 to 3 or a pharmaceutical composition as described in any one of embodiments 4 to 8 and at least one direct-acting antiviral drug (DAA) during a treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a terminating dose of the compound or pharmaceutical composition is administered at the end of the treatment period, and the terminating dose is the only dose of the compound or pharmaceutical composition administered during the treatment period.
[0023] Embodiment 17. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 2 to 10 weeks, 4 to 8 weeks, 2 to 6 weeks, or 1 to 4 weeks.
[0024] Embodiment 18. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 11 weeks, 10 weeks, 9 weeks, 8 weeks, 7 weeks, 6 weeks, 5 weeks, 4 weeks, 3 weeks, 2 weeks or 1 week.
[0025] Embodiment 19. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 26, 27, 28, 29 or 30 days.
[0026] Embodiment 20. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 28 or 29 days.
[0027] Embodiment 21. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 18, 19, 20, 21 or 22 days.
[0028] Embodiment 22. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 21 or 22 days.
[0029] Embodiment 23. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 12, 13, 14, 15 or 16 days.
[0030] Embodiment 24. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 14 or 15 days.
[0031] Embodiment 25. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 6, 7, 8 or 9 days.
[0032] Embodiment 26. The method of any one of embodiments 13 to 16, wherein the duration of the treatment period is 7 or 8 days.
[0033] Embodiment 27. The method of any one of Embodiments 13 to 15 or 17 to 26, wherein the starting dose of the compound or pharmaceutical composition and the first dose of the DAA are administered within 7 days of each other.
[0034] Embodiment 28. The method of any one of Embodiments 13 to 15 or 17 to 26, wherein the starting dose of the compound or pharmaceutical composition is administered one day prior to the first dose of the DAA.
[0035] Embodiment 29. The method of any one of embodiments 13 to 15 or 17 to 26, wherein the starting dose of the compound or pharmaceutical composition is administered on the same day as the first dose of the DAA.
[0036] Embodiment 30. The method of any one of embodiments 13 to 15 or 17 to 26, wherein the starting dose of the compound or pharmaceutical composition is administered one day after the first dose of the DAA.
[0037] Embodiment 31. The method of any one of embodiments 13, 14, or 16 to 26, wherein the final dose of the compound or pharmaceutical composition and the last dose of the DAA are administered within 7 days of each other.
[0038] Embodiment 32. The method of any one of embodiments 13, 14, or 16 to 26, wherein the terminal dose of the compound or pharmaceutical composition is administered 1 day prior to the last dose of the DAA.
[0039] Embodiment 33. The method of any one of embodiments 13, 14, or 16 to 26, wherein the final dose of the compound or pharmaceutical composition is administered on the same day as the last dose of the DAA.
[0040] Embodiment 34. The method of any one of embodiments 13, 14, or 16 to 26, wherein the terminal dose of the compound or pharmaceutical composition is administered 1 day after the last dose of the DAA.
[0041] Embodiment 35. The method of any one of embodiments 12 to 34, wherein the HCV infected subject is infected with genotype 1.
[0042] Embodiment 36. The method of embodiment 35, wherein the HCV infected subject is infected with genotype 1a.
[0043] Embodiment 37. The method of embodiment 35, wherein the HCV infected subject is infected with genotype 1b.
[0044] Embodiment 38. The method of any one of embodiments 12 to 34, wherein the HCV infected subject is infected with genotype 2.
[0045] Embodiment 39. The method of any one of embodiments 12 to 34, wherein the HCV infected subject is infected with genotype 3.
[0046] Embodiment 40. The method of any one of embodiments 12 to 34, wherein the HCV infected subject is infected with genotype 4.
[0047] Embodiment 41. The method of any one of embodiments 12 to 34, wherein the HCV infected subject is infected with genotype 5.
[0048] Embodiment 42. The method of any one of embodiments 12 to 34, wherein the HCV infected subject is infected with genotype 6.
[0049] Embodiment 43. The method of any one of embodiments 12 to 42, wherein the HCV infected subject is determined to be infected with HCV having one or more resistance-associated polymorphisms.
[0050] Embodiment 44. The method of any one of embodiments 12 to 43, wherein the HCV infected subject is a treatment-naive subject.
[0051] Embodiment 45. The method of any one of embodiments 12 to 44, wherein the HCV-infected subject suffers from an HCV-related disease.
[0052] Embodiment 46. The method of embodiment 45, wherein the HCV-related disease is cirrhosis, liver fibrosis, steatohepatitis, steatosis, or hepatocellular carcinoma.
[0053] Embodiment 47. The method of any one of embodiments 12 to 46, wherein the HCV infected subject is an HCV infected subject with renal impairment.
[0054] Embodiment 48. The method of any one of embodiments 12 to 47, wherein the HCV infected subject is an HCV / HIV co-infected subject.
[0055] Embodiment 49. The method of any one of embodiments 12 to 48, wherein said administration achieves a sustained viral response.
[0056] Embodiment 50. The method of any one of embodiments 13 to 49, wherein the HCV RNA level is below the lower limit of quantification (LLOQ) at the end of the treatment period or at a time point after the end of the treatment period.
[0057] Embodiment 51. The method of embodiment 50, wherein the HCV RNA level is below LLOQ 4 weeks after the end of the treatment period.
[0058] Embodiment 52. The method of embodiment 50 or embodiment 51, wherein the HCV RNA level is below LLOQ 8 weeks after the end of the treatment period.
[0059] Embodiment 53. The method of any one of embodiments 50 to 52, wherein the HCV RNA level is below LLOQ 12 weeks after the end of the treatment period.
[0060] Embodiment 54. The method of any one of embodiments 50 to 53, wherein the HCV RNA level is below LLOQ 24 weeks after the end of the treatment period.
[0061] Embodiment 55. The method of any one of embodiments 50 to 54, wherein the HCV RNA level is below LLOQ at 36 weeks after the end of the treatment period.
[0062] Embodiment 56. The method of any one of embodiments 50 to 55, wherein the HCV RNA level is below LLOQ at 48 weeks after the end of the treatment period.
[0063] Embodiment 57. The method of any one of embodiments 50 to 56, wherein the LLOQ is 25 IU / mL.
[0064] Embodiment 58. The method of any one of embodiments 50 to 56, wherein the LLOQ is 15 IU / mL.
[0065] Embodiment 59. The method of any one of embodiments 50 to 56, wherein the LLOQ is 12 IU / mL.
[0066] Embodiment 60. The method of any one of embodiments 50 to 59, wherein the HCV RNA level is quantified using a real-time polymerase chain reaction based assay.
[0067] Embodiment 61. The method of any one of embodiments 13 to 60, wherein the DAA is administered daily.
[0068] Embodiment 62. A method as described in any one of embodiments 13 to 61, wherein the DAA is selected from a protease inhibitor, a nucleoside polymerase inhibitor, a nucleotide polymerase inhibitor, a non-nucleoside polymerase inhibitor, an NS3B inhibitor, an NS3 / 4A inhibitor, an NS4A inhibitor, an NS5A inhibitor, an NS5B inhibitor and a cyclophilin inhibitor.
[0069] Embodiment 63. The method of any one of embodiments 13 to 62, wherein the DAA is selected from one or more of the following: sofosbuvir, ledipasvir, ombitasvir, dasabuvir, glecaprevir, pibrentasvir, elbasvir, grazoprevir, ribavirin, ombitasvir, paritaprevir , ritonavir, boceprevir, vaniprevir, asunaprevir, daclatasvir, simeprevir, mericitabine, tegobuvir, danoprevir, sovaprevir, voxilaprevir, velpatasvir, and GSK2878175.
[0070] Embodiment 64. The method of any one of Embodiments 13 to 63, wherein the at least one DAA comprises sofosbuvir.
[0071] Embodiment 65. The method of any one of Embodiments 13 to 64, wherein the at least one DAA comprises ledipasvir and sofosbuvir.
[0072] Embodiment 66. The method of any one of Embodiments 12 to 65, wherein the dose of the compound is less than or equal to 4.0 mg / kg, less than or equal to 3.5 mg / kg, less than or equal to 3.0 mg / kg, less than or equal to 2.5 mg / kg, less than or equal to 2.0 mg / kg, less than or equal to 1.5 mg / kg, less than or equal to 1.0 mg / kg, or less than or equal to 0.5 mg / kg.
[0073] Embodiment 67. A compound according to any one of embodiments 1 to 3 or a pharmaceutical composition according to any one of embodiments 4 to 8 for use in therapy.
[0074] Embodiment 68. The compound according to any one of embodiments 1 to 3 or the pharmaceutical composition according to any one of embodiments 4 to 8, for use in treating a subject infected with HCV. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1 . HCV RNA was reduced in the serum of HCV-infected mouse models after treatment with PBS, RG-101, or RG6650. DETAILED DESCRIPTION
[0076] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. Unless a specific definition is provided, the terms used in conjunction with analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry described herein, as well as their procedures and techniques, are well known and commonly used in the art. In the case where there are multiple definitions for the terms herein, the definitions in this section shall prevail. Standard techniques can be used for chemical synthesis, chemical analysis, drug preparation, formulation and delivery, and treatment of subjects. Some such techniques and procedures can be found, for example, in "Carbohydrate Modifications in Antisense Research", edited by Sangvi and Cook, American Chemical Society, Washington DC, 1994; and "Remington's Pharmaceutical Sciences", Mack Publishing Co., Easton, Pa., 18th edition, 1990; and for any purpose, the references are incorporated herein by reference. Where permitted, unless otherwise noted, all patents, patent applications, published applications and publications, GENBANK sequences, websites, and other disclosed materials referred to throughout the entire disclosure herein are incorporated herein by reference as a whole. It should be understood that where a URL or other such identifier or address is referenced, such identifiers may vary, and particular information on the Internet may also vary, but equivalent information may be found by searching the Internet. Such reference evidences the availability and public dissemination of such information.
[0077] Before disclosing and describing the present compositions and methods, it should be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms "a / an", "the" and "the" include plural referents unless the context clearly indicates otherwise.
[0078] definition
[0079] "HCV infection" means infection with one or more genotypes of the Hepatitis C virus.
[0080] "HCV infected subject" means a subject that has been infected with one or more genotypes of the hepatitis C virus. An HCV infected subject may or may not show symptoms of HCV infection. An HCV infected subject includes a subject that has been infected with one or more genotypes of HCV, but the HCV RNA in the blood of the subject is below detectable levels.
[0081] "Treatment-naive HCV-infected subject" means an HCV-infected subject who has not received treatment for a previous HCV infection.
[0082] "HCV-related diseases" refers to pathological processes mediated by HCV infection. HCV-related diseases include, but are not limited to, cirrhosis, liver fibrosis, steatohepatitis, and hepatocellular carcinoma.
[0083] "Blood HCV RNA" means the hepatitis C virus RNA present in the blood of an HCV infected subject. Blood includes whole blood and serum.
[0084] "Blood" means whole blood and blood fractions, such as serum and plasma.
[0085] "Serum HCV RNA rebound" means an increase in HCV RNA levels following a previous decrease in HCV RNA levels.
[0086] "HCV RNA level" means the amount of HCV RNA in a given volume of a subject's blood. The HCV RNA level can be expressed as the number of RNA copies per milliliter. "HCV RNA level" may also be referred to as "HCV viral load" or "HCV RNA titer." HCV RNA levels can be measured using an in vitro reverse transcription polymerase chain reaction assay.
[0087] "Sustained viral response" means that the hepatitis C virus RNA in the subject's blood is undetectable at the end of the entire course of treatment and after an additional 12 weeks. In certain embodiments, HCV RNA is considered undetectable below 40 copies per milliliter of blood.
[0088] "SVRX" (where X is the number of weeks after the end of the treatment period) means the sustained viral response at that time point after the end of the treatment period. For example, SVR8 is a sustained viral response 8 weeks after the end of the treatment period.
[0089] "Non-responder" means a subject who has received treatment but has not experienced a clinically acceptable improvement in disease markers or symptoms.
[0090] "Interferon non-responder" means a subject with HCV infection who has received treatment with interferon but has not experienced a clinically acceptable reduction in HCV RNA levels.
[0091] "Direct-acting antiviral agent" or "DAA" means an agent that inhibits HCV activity by directly interacting with proteins encoded by the HCV genome. A DAA can be an inhibitor of NS3 / 4A protease, NS5A nonstructural protein, or NS5B polymerase. A DAA can be a nucleoside compound or a non-nucleoside compound.
[0092] "Direct acting antiviral drug non-responder" means a subject with HCV infection who has received treatment with a direct acting antiviral agent but has not experienced a clinically acceptable reduction in HCV RNA levels. In certain embodiments, the virus has developed resistance to the direct acting antiviral agent.
[0093] "Renal impairment" means a condition in which the kidneys cannot adequately filter waste products from the blood. Renal impairment can be determined by estimated glomerular filtration rate or measured glomerular filtration rate. Renal impairment can also be determined by creatinine clearance.
[0094] "miR-122-associated disorder" means any disease, condition or disorder that can be treated, prevented or ameliorated by regulating miR-122. miR-122-associated diseases need not be characterized by excess miR-122. miR-122-associated diseases include, but are not limited to, HCV infection, elevated cholesterol, and iron overload disorders.
[0095] "Iron overload disorder" means any disease, disorder, or condition characterized by an excess of iron in the body.
[0096] "Subject" means a human selected for treatment or therapy.
[0097] "Subject in need thereof" means a subject identified as being in need of therapy or treatment.
[0098] A "subject suspected of having" means a subject who exhibits one or more clinical indicators of a disease.
[0099] "Administering" means providing an agent or composition to a subject, and includes, but is not limited to, administration by a medical professional and self-administration.
[0100] "Parenteral administration" means administration by injection or infusion. Parenteral administration includes, but is not limited to, subcutaneous administration, intravenous administration, and intramuscular administration.
[0101] "Subcutaneous administration" means administration beneath the skin.
[0102] "Intravenous administration" means administration into a vein.
[0103] "Simultaneous administration" refers to the co-administration of two or more agents to a subject in any manner, wherein the pharmacological effects of each agent are present in the subject. Simultaneous administration does not require that the two agents be administered in a single pharmaceutical composition, in the same dosage form, or by the same route of administration. The effects of the two agents do not need to be present at the same time. The effects need only overlap for a period of time and do not need to be co-existent.
[0104] "Duration" means the period of time over which an activity or event lasts. In certain embodiments, the duration of treatment is the period of time over which multiple doses of a pharmaceutical agent or pharmaceutical composition are administered.
[0105] "Therapy" means a method of treating a disease. In certain embodiments, therapy includes, but is not limited to, chemotherapy, radiation therapy, or administration of a pharmaceutical agent.
[0106] "Treatment" means the application of one or more specific procedures for curing or ameliorating a disease. In certain embodiments, the specific procedure is the administration of one or more pharmaceutical agents.
[0107] "Improvement" means reducing the severity of at least one indicator of a disorder or disease. In certain embodiments, improvement includes delaying or slowing the progression of one or more indicators of a disorder or disease. The severity of an indicator can be determined by subjective or objective measurements known to those skilled in the art.
[0108] "At risk of developing..." means a state in which a subject is susceptible to developing a disorder or disease. In certain embodiments, a subject at risk of developing a disorder or disease exhibits one or more symptoms of the disorder or disease, but does not exhibit a sufficient number of symptoms to be diagnosed with the disorder or disease. In certain embodiments, a subject at risk of developing a disorder or disease exhibits one or more symptoms of the disorder or disease, but to a lesser degree required to diagnose the disorder or disease.
[0109] "Preventing the onset of" means preventing the development of a disorder or disease in a subject at risk of developing the disease or disorder. In certain embodiments, a subject at risk of developing the disease or disorder receives a treatment similar to that received by a subject already suffering from the disease or disorder.
[0110] "Delaying onset" means delaying the development of a disorder or disease in a subject at risk of developing the disease or disorder. In certain embodiments, a subject at risk of developing the disease or disorder receives a treatment similar to that received by a subject already suffering from the disease or disorder.
[0111] "Therapeutic agent" means an agent used to cure, ameliorate or prevent disease.
[0112] "Dose" means a specified amount of a medicament provided in a single administration. In certain embodiments, a dose may be administered in two or more boluses, tablets, or injections. For example, in certain embodiments, where subcutaneous administration is desired, the desired dose requires a volume that is not easily provided by a single injection. In such embodiments, two or more injections may be used to achieve the desired dose. In certain embodiments, a dose may be administered in two or more injections to minimize injection site reactions in a subject. In certain embodiments, a dose is administered by slow infusion.
[0113] "Dosage unit" means the form in which a medicament is provided. In certain embodiments, a dosage unit is a vial containing a lyophilized oligonucleotide. In certain embodiments, a dosage unit is a vial containing a reconstituted oligonucleotide.
[0114] A "therapeutically effective amount" refers to an amount of an agent that provides a therapeutic benefit to an animal.
[0115] "Pharmaceutical composition" means a mixture of substances suitable for administration to a subject, including a pharmaceutical agent. For example, a pharmaceutical composition may include a sterile aqueous solution.
[0116] "Pharmaceutical agent" means a substance that provides a therapeutic effect when administered to a subject.
[0117] "Active pharmaceutical ingredient" means the substance in a pharmaceutical composition that provides the desired effect.
[0118] "Pharmaceutically acceptable salts" means physiologically and pharmaceutically acceptable salts of compounds provided herein, i.e., salts that retain the desired biological activity of the compound and do not have undesirable toxic effects when administered to a subject. Non-limiting exemplary pharmaceutically acceptable salts of compounds provided herein include sodium and potassium salt forms. Unless otherwise expressly indicated, the terms "compound", "oligonucleotide" and "modified oligonucleotide" as used herein include pharmaceutically acceptable salts thereof.
[0119] "Saline solution" means a solution of sodium chloride in water.
[0120] "Improved organ function" means a change in organ function toward normal limits. In certain embodiments, organ function is assessed by measuring molecules present in the blood or urine of the subject. For example, in certain embodiments, improved liver function is measured by a decrease in blood liver transaminase levels. In certain embodiments, improved renal function is measured by a decrease in blood urea nitrogen, a decrease in proteinuria, a decrease in albuminuria, etc.
[0121] An "acceptable safety profile" means a profile of side effects that is within clinically acceptable limits.
[0122] "Side effects" means physiological responses other than the desired effect that are attributable to the treatment. In certain embodiments, side effects include, but are not limited to, injection site reactions, abnormal liver function tests, abnormal renal function, hepatotoxicity, nephrotoxicity, central nervous system abnormalities, and myopathy. Such side effects can be detected directly or indirectly. For example, increased transaminase levels in serum can indicate hepatotoxicity or abnormal liver function. For example, increased bilirubin can indicate hepatotoxicity or abnormal liver function.
[0123] "Injection site reaction" means inflammation or unusual redness of the skin at the site of an injection in a subject.
[0124] "Subject compliance" means a subject's compliance with a recommended or prescribed therapy.
[0125] "Compliance" means that the subject obeys the recommended therapy.
[0126] “Recommended therapy” means a treatment recommended by a medical professional to cure, ameliorate, delay or prevent a disease.
[0127] "miR-122" refers to a microRNA having the nucleobase sequence UGGAGUGUGACAAUGGUGUUUG (SEQ ID NO: 1).
[0128] "Oligonucleotide" means a compound comprising a plurality of independently linked nucleosides, each of which may be modified or unmodified.
[0129] "Modified oligonucleotide" means a single-stranded oligonucleotide having one or more modifications relative to the naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages. A modified oligonucleotide may comprise unmodified nucleosides.
[0130] "Anti-miR" means a modified oligonucleotide having a nucleobase sequence complementary to a microRNA.
[0131] "Anti-miR-122" means a modified oligonucleotide having a nucleobase sequence complementary to miR-122. In certain embodiments, anti-miR-122 is completely complementary to miR-122 (i.e., 100% complementary). In certain embodiments, anti-miR-122 is at least 90%, at least 93%, at least 94%, at least 95%, or 100% complementary.
[0132] "Targeting" refers to the process of designing and selecting nucleobase sequences that will hybridize to a target nucleic acid.
[0133] "Targeting" means having a nucleobase sequence that will permit hybridization to a target nucleic acid.
[0134] "Modulate" means to interfere with a function, amount or activity. In certain embodiments, modulate means to increase a function, amount or activity. In certain embodiments, modulate means to decrease a function, amount or activity.
[0135] "Expression" refers to any function or step by which the coded information of a gene is converted into a structure that exists and functions in a cell.
[0136] "Nucleobase sequence" means the order of contiguous nucleobases in an oligomeric compound or nucleic acid, typically listed in the 5' to 3' direction, independent of any sugar, linkage and / or nucleobase modifications.
[0137] "Consecutive nucleobases" means nucleobases that are immediately adjacent to each other in a nucleic acid.
[0138] "Nucleobase complementarity" refers to the ability of two nucleobases to pair non-covalently via hydrogen bonding.
[0139] "Complementary" means that one nucleic acid is capable of hybridizing to another nucleic acid or oligonucleotide. In certain embodiments, complementary means that an oligonucleotide is capable of hybridizing to a target nucleic acid.
[0140] "Complete complementarity" means that each nucleobase of an oligonucleotide is able to pair with a nucleobase at each corresponding position in a target nucleic acid. In certain embodiments, an oligonucleotide is fully complementary to a microRNA (also referred to as 100% complementary), i.e., each nucleobase of the oligonucleotide is complementary to a nucleobase at a corresponding position in the microRNA. A modified oligonucleotide can be fully complementary to a microRNA and have many connected nucleosides that are less than the length of the microRNA. For example, an oligonucleotide with 10 connected nucleosides (where each nucleobase of the oligonucleotide is complementary to a nucleobase at a corresponding position in the microRNA) is fully complementary to a microRNA.
[0141] "Complementarity percentage" means the percentage of nucleobases in an oligonucleotide that are complementary to an equal length portion of a target nucleic acid. The complementarity percentage is calculated by dividing the number of nucleobases in the oligonucleotide that are complementary to nucleobases at corresponding positions in the target nucleic acid by the total number of nucleobases in the oligonucleotide.
[0142] "Percent identity" means the number of nucleobases in a first nucleic acid that are identical to the nucleobases at corresponding positions in a second nucleic acid divided by the total number of nucleobases in the first nucleic acid. In certain embodiments, the first nucleic acid is a microRNA and the second nucleic acid is a microRNA. In certain embodiments, the first nucleic acid is an oligonucleotide and the second nucleic acid is an oligonucleotide.
[0143] "Hybridization" means the annealing of complementary nucleic acids through nucleobase complementarity.
[0144] "Mismatch" refers to a base in a first nucleic acid that cannot undergo Watson-Crick pairing with a nucleobase at a corresponding position in a second nucleic acid.
[0145] "Identical" in the context of nucleobase sequences means having the same nucleobase sequence independent of sugar, linkage and / or nucleobase modifications and independent of the methyl state of any pyrimidines present.
[0146] "MicroRNA" means an endogenous non-coding RNA of a length between 18 and 25 nucleobases, which is the product of pre-microRNA cleavage by the enzyme Dicer. Examples of mature microRNAs can be found in the microRNA database known as miRBase (http: / / microrna.sanger.ac.uk / ). In certain embodiments, microRNA is abbreviated as "microRNA" or "miR".
[0147] "MicroRNA-regulated transcript" means a transcript that is regulated by a microRNA.
[0148] "Seed sequence" means the nucleobase sequence comprising nucleobases 2 to 7 of the 5'-end of the mature microRNA sequence.
[0149] "Seed matching sequence" means a nucleobase sequence that is complementary to a seed sequence and has the same length as the seed sequence.
[0150] "Naturally occurring internucleoside linkage" means a 3' to 5' phosphodiester linkage between nucleosides.
[0151] "Natural sugar" means a sugar found in DNA (2'-H) or RNA (2'-OH).
[0152] "Internucleoside linkage" means a covalent linkage between adjacent nucleosides.
[0153] "Linked nucleosides" means nucleosides linked by a covalent linkage.
[0154] "Nucleobase" means a heterocyclic moiety capable of non-covalently pairing with another nucleobase.
[0155] "Nucleoside" means a nucleobase linked to a sugar moiety.
[0156] "Nucleotide" means a nucleoside having a phosphate group covalently linked to the sugar portion of the nucleoside.
[0157] "A compound comprising a modified oligonucleotide consisting of a plurality of linked nucleosides" means a compound comprising a modified oligonucleotide having a specified number of linked nucleosides. Thus, the compound may comprise additional substituents or conjugates. Unless otherwise specified, the compound does not comprise any additional nucleosides beyond the nucleosides of the modified oligonucleotide.
[0158] "Modified nucleoside" means a nucleoside with any changes compared to a naturally occurring nucleoside. A modified nucleoside may have a modified sugar and an unmodified nucleobase. A modified nucleoside may have a modified sugar and a modified nucleobase. A modified nucleoside may have a natural sugar and a modified nucleobase. In certain embodiments, a modified nucleoside is a bicyclic nucleoside. In certain embodiments, a modified nucleoside is a non-bicyclic nucleoside.
[0159] "2'-modified nucleosides" means nucleosides containing any modified sugar at the position equivalent to the 2' position of the furanosyl ring when the positions are numbered in 2-deoxyribose or ribose. It should be understood that 2'-modified nucleosides include, but are not limited to, nucleosides containing bicyclic sugar moieties.
[0160] "Modified internucleoside linkage" means any change from a naturally occurring internucleoside linkage.
[0161] "Phosphorothioate internucleoside linkage" means a linkage between nucleosides in which one of the non-bridging atoms is a sulfur atom, i.e., OP(O)(S)O-. For the avoidance of doubt, the sulfur atom may be protonated or reacted with a counterion such as Na + , K + etc.) association.
[0162] "Phosphodiester linkage" means a linkage between nucleosides having the structure -OP(O)2O-. For the avoidance of doubt, one non-bridging oxygen may be protonated or reacted with a counterion (e.g., Na + , K + etc.) association.
[0163] By "unmodified nucleobases" is meant the naturally occurring heterocyclic bases of RNA or DNA: the purine bases adenine (A) and guanine (G); and the pyrimidine bases thymine (T), cytosine (C) (including 5-methylcytosine), and uracil (U).
[0164] "5-methylcytosine" means a cytosine comprising a methyl group attached to the 5 position of the cytosine ring.
[0165] "Unmethylated cytosine" means a cytosine that does not have a methyl group attached to the 5 position of the cytosine ring.
[0166] "Modified nucleobase" means any nucleobase that is not an unmodified nucleobase.
[0167] "Sugar moiety" means a naturally occurring furanosyl or a modified sugar moiety.
[0168] By "modified sugar moiety" is meant a substituted sugar moiety or sugar surrogate.
[0169] "2'-O-methyl sugar" or "2'-OMe sugar" means a sugar with an O-methyl modification at the 2' position.
[0170] "2'-O-methoxyethyl sugar" or "2'-MOE sugar" means a sugar with an O-methoxyethyl modification at the 2' position.
[0171] "2'-O-Fluoro" or "2'-F" means a sugar having a fluoro modification at the 2' position.
[0172] "Bicyclic sugar moiety" means a modified sugar moiety (including but not limited to furanosyl) comprising 4 to 7 rings, wherein the modified sugar moiety comprises a bridge connecting two atoms of the 4 to 7 rings to form a second ring, thereby producing a bicyclic structure. In certain embodiments, the 4 to 7 rings are sugar rings. In certain embodiments, the 4 to 7 rings are furanosyl. In certain such embodiments, the bridge connects the 2'-carbon and 4'-carbon of the furanosyl. Non-restrictive exemplary bicyclic sugar moieties include LNA, ENA, cEt, S-cEt and R-cEt.
[0173] "Locked nucleic acid (LNA) sugar moiety" means a substituted sugar moiety comprising a (CH2)-0 bridge between the 4' furanose ring atom and the 2' furanose ring atom.
[0174] "ENA sugar moiety" means a substituted sugar moiety comprising a (CH2)2-0 bridge between the 4' furanose ring atom and the 2' furanose ring atom.
[0175] "Constrained ethyl (cEt) sugar moiety" means a substituted sugar moiety comprising a CH(CH3)-O bridge between the 4' furanose ring atom and the 2' furanose ring atom. In certain embodiments, the CH(CH3)-O bridge is constrained in the S orientation. In certain embodiments, the CH(CH3)-O bridge is constrained in the R orientation.
[0176] "S-cEt sugar moiety" means a substituted sugar moiety comprising an S-constrained CH(CH3)-0 bridge between the 4' furanose ring atom and the 2' furanose ring atom.
[0177] "R-cEt sugar moiety" means a substituted sugar moiety comprising an R-constrained CH(CH3)-0 bridge between the 4' furanose ring atom and the 2' furanose ring atom.
[0178] "2'-O-methyl nucleoside" means a modified nucleoside having a 2'-O-methyl sugar modification.
[0179] "2'-O-methoxyethyl nucleoside" means a modified nucleoside having a 2'-O-methoxyethyl sugar modification. The 2'-O-methoxyethyl nucleoside may comprise a modified or unmodified nucleobase.
[0180] "2'-fluoro nucleoside" means a modified nucleoside having a 2'-fluoro sugar modification. A 2'-fluoro nucleoside may comprise a modified or unmodified nucleobase.
[0181] "Bicyclic nucleoside" means a modified nucleoside having a bicyclic sugar moiety. Bicyclic nucleosides can have modified or unmodified nucleobases.
[0182] "cEt nucleoside" means a nucleoside comprising a cEt sugar moiety. The cEt nucleoside may comprise a modified or unmodified nucleobase.
[0183] "S-cEt nucleoside" means a nucleoside comprising an S-cEt sugar moiety.
[0184] "R-cEt nucleoside" means a nucleoside comprising an R-cEt sugar moiety.
[0185] "β-D-deoxyribonucleoside" means a naturally occurring DNA nucleoside.
[0186] "β-D-ribonucleoside" means a naturally occurring RNA nucleoside.
[0187] "LNA nucleoside" means a nucleoside comprising an LNA sugar moiety.
[0188] "ENA nucleoside" means a nucleoside comprising an ENA sugar moiety.
[0189] As used herein, a "linking group" refers to an atom or group of atoms that links a first chemical entity to a second chemical entity via one or more covalent bonds.
[0190] As used herein, "joint" refers to an atom or a group of atoms that connects one or more ligands to a modified or unmodified nucleoside via one or more covalent bonds. The modified or unmodified nucleoside may be part of a modified oligonucleotide as described herein, or may be connected to a modified oligonucleotide by a phosphodiester or thiophosphate bond. In some embodiments, the joint connects one or more ligands to the 3' end of a modified oligonucleotide. In some embodiments, the joint connects one or more ligands to the 5' end of a modified oligonucleotide. In some embodiments, the joint connects one or more ligands to a modified or unmodified nucleoside, and the modified or unmodified nucleoside is connected to the 3' end of a modified oligonucleotide. In some embodiments, the joint connects one or more ligands to a modified or unmodified nucleoside, and the modified or unmodified nucleoside is connected to the 5' end of a modified oligonucleotide. When the linker connects one or more ligands to the 3' end of a modified oligonucleotide or to a modified or unmodified nucleoside at the 3' end of a modified oligonucleotide, in some embodiments, the point of attachment of the linker can be the 3' carbon of a modified or unmodified sugar moiety. When the linker connects one or more ligands to the 5' end of a modified oligonucleotide or to a modified or unmodified nucleoside at the 5' end of a modified oligonucleotide, in some embodiments, the point of attachment of the linker can be the 5' carbon of a modified or unmodified sugar moiety.
[0191] Overview
[0192] RG-101 is a GalNAc-conjugated modified oligonucleotide that targets miR-122. In a completed Phase I human proof-of-concept study, treatment with a single subcutaneous dose of RG-101 as monotherapy resulted in significant reductions in viral load in all treated HCV-infected subjects, including those with refractory genotypes, various liver fibrosis states, and those who experienced viral relapse after a previous IFN-containing regimen.
[0193] In the completed Phase II study evaluating RG-101 in combination with multiple approved direct-acting antivirals (DAAs), patients receiving RG-101 and All subjects experienced significant and sustained reductions in viral load throughout the 48-week follow-up period. TM or In the group with 100% response rate, the response rate was less than 100%. In the Phase 2 study, 10 of 200 subjects experienced transient hyperbilirubinemia, characterized by increases in conjugated bilirubin and total bilirubin exceeding the upper limit of normal (ULN). The U.S. Food and Drug Administration has placed a clinical hold on the IND for RG-101 for the treatment of chronic HCV infection.
[0194] Although other subject-specific contributing factors cannot be definitively ruled out, as described herein, it is believed that inhibition of conjugated bilirubin transport by RG-101 may contribute to the observed hyperbilirubinemia. In light of this, a screen was conducted for alternative compounds targeting miR-122 that retained potent HCV antiviral activity and had an appropriate safety profile, including no substantial interference with bilirubin transport via the MRP2 transporter. This screening process identified compound RG6650 as an anti-miR-122 compound that met these criteria.
[0195] Certain anti-miR-122 compounds
[0196] Provided herein is a compound designated as RG6650, comprising a GalNAc-containing conjugate moiety and a modified oligonucleotide complementary to miR-122. The modified oligonucleotide is designated as RG7443 and has a structure U S C S AC S AC S TC S C S , wherein the nucleoside without a subscript following it is a β-D-deoxyribonucleoside, the nucleoside with a subscript "S" following it is an S-cEt nucleoside, and each internucleoside linkage is a phosphorothioate internucleoside linkage.
[0197] In certain embodiments, compound RG6650 is represented by the following structure:
[0198]
[0199] wherein MO is a modified oligonucleotide having the structure U S C S AC S AC S TC S C S , wherein the nucleoside without a subscript following it is a β-D-deoxyribonucleoside, the nucleoside with a subscript "S" following it is an S-cEt nucleoside, and each internucleoside linkage is a phosphorothioate internucleoside linkage; wherein X1 is a phosphodiester linkage; m is 1; N is β-D-deoxyriboadenosine; X2 is a phosphodiester linkage; and wherein the conjugate moiety is attached to the 3' terminus of the modified oligonucleotide.
[0200] In certain embodiments, compound RG6650 is represented by the following structure:
[0201]
[0202] or a pharmaceutically acceptable salt thereof.
[0203] In each internucleoside linkage (e.g., each phosphorothioate linkage and each phosphodiester linkage), a non-bridging heteroatom (e.g., S - or - ) can be protonated or reacted with counterions such as Na + , K + Pharmaceutically acceptable salts of compounds may contain fewer cationic counterions (e.g., Na + , K + In some embodiments, the pharmaceutically acceptable salt of RG6650 comprises less than 10 cationic counterions (e.g., Na, etc.) per molecule of RG6650. + , K + That is, in some embodiments, the pharmaceutically acceptable salt of RG6650 may contain an average of 1, 2, 3, 4, 5, 6, 7, 8, or 9 cationic counterions per molecule of RG6650, with the remaining phosphorothioate and / or phosphodiester linkages being protonated.
[0204] Provided herein are pharmaceutical compositions comprising a compound provided herein and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is an aqueous solution. In certain embodiments, the aqueous solution is a saline solution. As used herein, a pharmaceutically acceptable diluent is understood to be a sterile diluent.
[0205] In certain embodiments, the pharmaceutical compositions provided herein are administered by subcutaneous injection.Other suitable routes of administration include, but are not limited to, intravenous administration, oral administration, and intramuscular administration.
[0206] Certain uses of anti-miR-122 compounds and compositions
[0207] Provided herein are methods for treating HCV infection, comprising administering to an HCV infected subject at least one dose of a compound or pharmaceutical composition provided herein. In certain embodiments, provided herein are methods comprising selecting an HCV infected subject.
[0208] Although current direct-acting antiviral drugs are achieving a high rate of sustained viral response, there is still an underserved population of HCV infected subjects who do not respond to current treatments or relapse after successful treatment. Resistance to antiviral therapy is a major problem associated with the high mutation rate of HCV and can be observed even with drug combinations. In addition, HCV infected subjects need to take oral agents at least once a day for a long time (e.g., for Poor compliance with a treatment regimen of (12 weeks) can interfere with achieving a high response rate. Combining an anti-miR-122 therapeutic agent targeting the viral host factor miR-122 and one or more direct-acting antiviral agents represents an opportunity to achieve a higher and more durable cure rate, for example, by improving subject compliance, reducing side effects and / or higher efficacy. Therefore, in certain embodiments, various methods are provided herein, comprising administering a compound or pharmaceutical composition provided herein and at least one direct-acting antiviral agent (DAA) simultaneously during treatment.
[0209] In certain embodiments, the treatment period is substantially shorter than the treatment period of at least one DAA alone.
[0210] Provided herein are methods for treating hepatitis C virus (HCV) infection, comprising administering a compound or pharmaceutical composition provided herein and at least one direct-acting antiviral (DAA) to an HCV-infected subject during a treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a starting dose of the compound or pharmaceutical composition is administered at the beginning of the treatment period and a terminating dose of the compound or pharmaceutical composition is administered at the end of the treatment period. In certain embodiments, the starting dose and terminating dose are the only doses of the compound or pharmaceutical composition administered during the treatment period.
[0211] Provided herein are methods for treating HCV infection, comprising administering a compound or pharmaceutical composition provided herein and at least one DAA to an HCV-infected subject during a treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a starting dose of the compound or pharmaceutical composition is administered at the beginning of the treatment period and the starting dose is the only dose of the compound or pharmaceutical composition administered during the treatment period.
[0212] Provided herein are methods for treating HCV infection, comprising administering a compound or pharmaceutical composition provided herein and at least one DAA to an HCV-infected subject during a treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a terminating dose of the compound or pharmaceutical composition is administered at the end of the treatment period, and the terminating dose is the only dose of the compound or pharmaceutical composition administered during the treatment period.
[0213] In any of the methods provided herein, the duration of the treatment period is 11 weeks or less, 10 weeks or less, 9 weeks or less, 8 weeks or less, 7 weeks or less, 6 weeks or less, 5 weeks or less, 4 weeks or less, 2 weeks or less, or 1 week or less. In any of the methods provided herein, the duration of the treatment period is 1 to 12 weeks, 2 to 10 weeks, 4 to 8 weeks, 2 to 6 weeks or 1 to 4 weeks. In any of the methods provided herein, the duration of the treatment period is 11 weeks, 10 weeks, 9 weeks, 8 weeks, 7 weeks, 6 weeks or 5 weeks. In certain embodiments, the duration of the treatment period is 11 weeks. In certain embodiments, the duration of the treatment period is 10 weeks. In certain embodiments, the duration of the treatment period is 9 weeks. In certain embodiments, the duration of the treatment period is 8 weeks. In certain embodiments, the duration of the treatment period is 7 weeks. In certain embodiments, the duration of the treatment period is 6 weeks. In certain embodiments, the duration of the treatment period is 5 weeks.
[0214] In certain embodiments, the duration of the treatment period is 4 weeks. In certain embodiments, the duration of the treatment period is 3 weeks. In certain embodiments, the duration of the treatment period is 2 weeks. In certain embodiments, the duration of the treatment period is 1 week. In certain embodiments, the duration of the treatment period is 26, 27, 28, 29 or 30 days. In certain embodiments, the duration of the treatment period is 28 or 29 days. In certain embodiments, the duration of the treatment period is 18, 19, 20, 21 or 22 days. In certain embodiments, the duration of the treatment period is 21 days. In certain embodiments, the duration of the treatment period is 12, 13, 14, 15 or 16 days. In certain embodiments, the duration of the treatment period is 14 or 15 days. In certain embodiments, the duration of the treatment period is 6, 7 or 8 days. In certain embodiments, the duration of the treatment period is 7 or 8 days.
[0215] In certain embodiments, the starting dose of a compound or pharmaceutical composition and the first dose of at least one DAA are administered within 7 days of each other. In certain embodiments, the starting dose of a compound or pharmaceutical composition is administered 1 day before the first dose of at least one DAA. In certain embodiments, the starting dose of a compound or pharmaceutical composition is administered on the same day as the first dose of at least one DAA. In certain embodiments, the starting dose of a compound or pharmaceutical composition is administered 1 day after the first dose of at least one DAA. In certain embodiments, the ending dose of a compound or pharmaceutical composition and the last dose of at least one DAA are administered within 7 days of each other. In certain embodiments, the ending dose of a compound or pharmaceutical composition is administered 1 day before the last dose of at least one DAA. In certain embodiments, the ending dose of a compound or pharmaceutical composition is administered on the same day as the last dose of at least one DAA. In certain embodiments, the ending dose of a compound or pharmaceutical composition is administered 1 day after the last dose of at least one DAA.
[0216] In certain embodiments, the compounds provided herein are administered at doses of 5 mg / kg or less, 4.5 mg / kg or less, 4 mg / kg or less, 3.5 mg / kg or less, 3 mg / kg or less, 2.5 mg / kg or less, 2 mg / kg or less, 1.5 mg / kg or less, 1 mg / kg or less, 0.75 mg / kg or less, 0.5 mg / kg or less, or 0.25 mg / kg or less.
[0217] In certain embodiments, the HCV infected subject is infected with genotype 1. In certain embodiments, the HCV infected subject is infected with genotype 1a. In certain embodiments, the HCV infected subject is infected with genotype 1b. In certain embodiments, the HCV infected subject is infected with genotype 2. In certain embodiments, the HCV infected subject is infected with genotype 3. In certain embodiments, the HCV infected subject is infected with genotype 4. In certain embodiments, the HCV infected subject is infected with genotype 5. In certain embodiments, the HCV infected subject is infected with genotype 6.
[0218] In certain embodiments, the HCV infected subject is infected with genotype 1a, genotype 1b, genotype 2a, genotype 2b, genotype 2c, genotype 2d, genotype 3a, genotype 3b, genotype 3c, genotype 3d, genotype 3e, genotype 3f, genotype 4a, genotype 4b, genotype 4c, genotype 4d, genotype 4e, genotype 4f, genotype 4g, genotype 4h, genotype 4i, genotype 4j, genotype 5a, or genotype 6a.
[0219] The HCV genome encodes several proteins that are critical for viral RNA replication and virion assembly. The HCV genome is capable of high-speed mutations. In some cases, treatment with DAAs results in the appearance of nucleotide sequence polymorphisms, which may be related to viral resistance to DAAs. Therefore, provided herein is a method for treating HCV-infected subjects infected with an HCV genotype having one or more resistance-associated polymorphisms. In certain embodiments, the presence of one or more resistance-associated polymorphisms in HCV-infected subjects is tested before treatment. In some embodiments, the presence of polymorphisms can be determined by sequencing of HCV RNA.
[0220] In certain embodiments, there are nucleotide changes in HCV RNA encoding one or more amino acid polymorphisms in one or more HCV encoded proteins. In certain embodiments, the amino acid polymorphism is in the NS5A protein encoded by HCV. In certain embodiments, the NS5A amino acid polymorphism is at one or more of the amino acid positions M28, Q30, L31 and Y93 of the NS5A protein. In certain embodiments, the amino acid polymorphism is in the NS3 protein encoded by HCV. In certain embodiments, the amino acid polymorphism is at one or more of the positions Q80, S122, R155, D168 and D169 of the NS3 protein. In certain embodiments, the amino acid polymorphism is in the NS4A protein encoded by HCV. In certain embodiments, the amino acid polymorphism is in the NS4B protein encoded by HCV. In certain embodiments, the amino acid polymorphism is in the NS5B protein encoded by HCV.
[0221] In certain embodiments, the HCV infected subject is an untreated HCV infected subject, i.e., the subject has not been treated before being selected for treatment as provided herein. In certain embodiments, treatment does not include administering interferon to the HCV infected subject. In certain embodiments, the HCV infected subject is an interferon non-responder. In certain embodiments, the HCV infected subject is a direct acting antiviral non-responder.
[0222] HCV infected subjects may develop HCV related diseases. The main liver disease consequence of HCV infection is cirrhosis and its complications, including bleeding, liver dysfunction and hepatocellular carcinoma. Another complication is fibrosis, which is the result of chronic inflammation that causes deposition of extracellular matrix components, which causes distortion of liver architecture and obstruction of microcirculation and liver function. Another complication of HCV infection is fatty degeneration, which in turn can lead to extrahepatic lesions, including diabetes, protein malnutrition, hypertension, cytotoxins, obesity and hypoxia. As the severity of complications increases, the liver may eventually fail, and HCV infected subjects may need liver transplantation. HCV infected subjects may also develop into hepatocellular carcinoma. In certain embodiments, HCV infected subjects suffer from HCV related diseases. In certain embodiments, HCV related diseases are cirrhosis, fibrosis, steatohepatitis, fatty degeneration and / or hepatocellular carcinoma.
[0223] In certain embodiments, the HCV infected subject is a liver transplant recipient.
[0224] In certain embodiments, HCV infects the subject and infects one or more viruses that are different from HCV. In certain embodiments, HCV infects the subject and is a HCV / HIV co-infected subject, i.e., the subject infects both HCV and HIV. In certain embodiments, the method provided herein includes administering an antiviral agent for the treatment of HIV infection. In certain embodiments, another therapeutic agent is a non-nucleoside reverse transcriptase inhibitor (NNRTI). In certain embodiments, another therapeutic agent is a nucleoside reverse transcriptase inhibitor (NRTI). In certain embodiments, another therapeutic agent is a protease inhibitor. In certain embodiments, another therapeutic agent is an entry inhibitor or a fusion inhibitor. In certain embodiments, another therapeutic agent is an integrase inhibitor. In certain embodiments, the additional therapeutic agent is selected from efavirenz, etravirine, nevirapine, abacavir, emtricitabine, tenofovir, lamivudine, zidovudine, atazanavir, darunavir, fosamprenavir, ritonavir, enfuvirtide, maraviroc, and raltegravir.
[0225] In certain embodiments, the HCV infected subject is an HCV infected subject with renal impairment. Renal impairment can be assessed by measuring the estimated glomerular filtration rate (eGFR). In certain embodiments, the subject suffers from mild renal impairment. In certain embodiments, mild renal impairment is characterized by 60-89 ml / min / 1.73 m 2 In certain embodiments, the subject has moderate renal impairment. In certain embodiments, moderate renal impairment is characterized by 30-59 ml / min / 1.73 m 2 In certain embodiments, the subject has severe renal impairment. In certain embodiments, severe renal impairment is characterized by 15-29 ml / min / 1.73 m 2 In some embodiments, the subject is experiencing renal failure. In some embodiments, the subject experiencing renal failure has a glomerular filtration rate of less than 15 ml / min / 1.73 m 2 The dose of the compound or DAA administered to HCV-infected subjects with renal impairment may be adjusted to be higher or lower than the dose administered to subjects without renal impairment, depending on the pharmacokinetic behavior of the drug in subjects with renal impairment.
[0226] In certain embodiments, provided herein are treatments for symptoms of HCV infection. Although HCV infection is usually asymptomatic, when present, symptoms of HCV infection include, but are not limited to, pain in or around the liver, jaundice, nausea, loss of appetite, and fatigue.
[0227] HCV RNA levels can be used to diagnose HCV infection, monitor disease activity and / or monitor the response of HCV infected subjects to treatment. In certain embodiments, the treatment provided herein reduces HCV RNA levels. In certain embodiments, the method provided herein includes administering a compound or pharmaceutical composition and DAA that can effectively treat the amount of HCV infection. In certain embodiments, the method provided herein includes selecting an experimenter whose HCV RNA level is greater than 350,000 copies / ml of serum, between 350,000 and 3,500,000 copies / ml of serum, or greater than 3,500,000 copies / ml of serum. In certain embodiments, the method provided herein includes reducing HCV RNA levels. In certain embodiments, the method provided herein includes reducing HCV RNA levels to less than 200 copies / ml of serum, less than 100 copies / ml of serum, less than 40 copies / ml of serum. HCV RNA levels can be referred to as "viral load" or "HCV RNA titer".
[0228] The variation of HCV RNA level can be described as log variation.For example, a decrease from 60,000 to 600 will be a 2-log decrease in HCV RNA level.In certain embodiments, the method provided herein realizes that HCV RNA level reduces by more than or equal to 2 logs.In certain embodiments, the method provided herein realizes that HCV RNA level reduces by at least 0.5 times, at least 1 times, at least 1.5 times, at least 2 times, at least 10 times, at least 50 times, at least 100 times, at least 500 times, at least 1000 times, at least 5000 times or at least 10,000 times.
[0229] In certain embodiments, the method provided herein includes realizing sustained viral response.In certain embodiments, before or at the end of the treatment period, HCV RNA levels are lower than the lower limit of quantification (LLOQ).In certain embodiments, 4 weeks after the end of the treatment period, HCV RNA levels are lower than LLOQ.In certain embodiments, 8 weeks after the end of the treatment period, HCV RNA levels are lower than LLOQ.In certain embodiments, 12 weeks after the end of the treatment period, HCV RNA levels are lower than LLOQ.In certain embodiments, 24 weeks after the end of the treatment period, HCV RNA levels are lower than LLOQ.In certain embodiments, 36 weeks after the end of the treatment period, HCV RNA levels are lower than LLOQ.In certain embodiments, 48 weeks after the end of the treatment period, HCV RNA levels are lower than LLOQ.In certain embodiments, LLOQ is 25IU / mL.In certain embodiments, LLOQ is 15IU / mL.In certain embodiments, LLOQ is 12IU / mL.
[0230] In certain embodiments, the HCV RNA level is quantified using a real-time polymerase chain reaction-based assay. The lower limit of quantification (LLOQ) of the assay may be different. For example, the lower limit of quantification (LLOQ) of the COBAS TaqMan HCV test (version 2.0) for high-definition systems is 25 IU / mL and the LLOQ of the COBAS AmpliPrep / COBAS Taqman HCV test (version 2.0) is 15 IU / mL. The lower limit of quantification (LLOQ) of the Abbott real-time HCV test is 12 IU / mL.
[0231] After the HCV treatment regimen, HCV infects the subject and can experience that HCV RNA level reduces, and then HCV RNA level increases, and described subsequent increase is called HCV RNA level rebound.In certain embodiments, the method that this paper provided prevents HCV RNA level rebound.In certain embodiments, the method that this paper provided delays HCV RNA level rebound.
[0232] In any of the embodiments provided herein, at least one DAA is administered once daily or twice daily. In certain embodiments, at least one DAA is administered once daily. In certain embodiments, at least one DAA is administered twice daily. In certain embodiments, at least one DAA is selected from NS3 / 4A protease inhibitors, NS5A inhibitors, nucleoside NS5B polymerase inhibitors, and non-nucleoside NS5B polymerase inhibitors. In certain embodiments, the NS5A inhibitor is ibasvir. In certain embodiments, the NS3 / 4A protease inhibitor is grazoprevir. In certain embodiments, the NS5A inhibitor is ombitasvir. In certain embodiments, the NS3 / 4A protease inhibitor is paritaprevir. In certain embodiments, the non-nucleoside NS5B polymerase inhibitor is dasbuvir. In certain embodiments, the NS5A inhibitor is daclatasvir. In certain embodiments, the NS3 / 4A protease inhibitor is simeprevir. In certain embodiments, the NS5A inhibitor is ledipasvir. In certain embodiments, the NS5B polymerase inhibitor is sofosbuvir. In certain embodiments, the NS3 / 4A inhibitor is glepuvir. In certain embodiments, the NS5A inhibitor is pibrentasvir.In certain embodiments, one or more direct acting antiviral agents are administered.
[0233] In certain embodiments, at least one DAA is selected from sofosbuvir, ledipasvir, ombitasvir, dasabuvir, ibasivir, grazoprevir, ribavirin, ombitasvir, paritasvir, ritonavir, boceprevir, vanirvir, asunaprevir, daclatasvir, simeprevir, mecitabine, tergobuvir, danoprevir, sovarprevir, gleprevir, pibrantavir, voxiprevir, velpatasvir and GSK2878175. In certain embodiments, at least one DAA is administered in an amount effective to treat HCV infection. In certain embodiments, the treatment period for which at least one DAA is administered is shorter than the treatment period specified for administering the DAA in the absence of the compound or pharmaceutical composition provided herein.
[0234] In certain embodiments, at least one DAA comprises sofosbuvir. In certain embodiments, at least one DAA comprises 400 mg sofosbuvir. In certain embodiments, at least one DAA is a tablet comprising 400 mg sofosbuvir, administered orally once daily. Sofosbuvir can be administered with or without ribavirin.
[0235] In certain embodiments, at least one DAA comprises ledipasvir and sofosbuvir. In certain embodiments, at least one DAA comprises ledipasvir administered at a dose of 90 mg ledipasvir and sofosbuvir at a dose of 400 mg. In certain embodiments, at least one DAA is a tablet comprising 90 mg ledipasvir and 400 mg sofosbuvir, administered orally once daily.
[0236] In certain embodiments, at least one DAA comprises simeprevir or a salt thereof. In certain embodiments, at least one DAA comprises simeprevir administered at a dose of 150 mg. In certain embodiments, at least one DAA is a capsule comprising 150 mg simeprevir, administered orally once daily.
[0237] In certain embodiments, at least one DAA comprises daclatasvir or a salt form thereof. In certain embodiments, at least one DAA comprises daclatasvir administered at a dose of 60 mg. In certain embodiments, at least one DAA is a tablet comprising 60 mg daclatasvir, administered orally once a day. In certain embodiments, at least one DAA is two tablets each comprising 30 mg daclatasvir, administered orally once a day. In certain embodiments, at least one DAA comprises daclatasvir administered at a dose of 60 mg and sofosbuvir administered at a dose of 400 mg. In certain embodiments, HCV-infected subjects are determined to be infected with an HCV genotype having one or more resistance-associated polymorphisms. In certain embodiments, the resistance-associated polymorphism is an NS5A polymorphism. In certain embodiments, the NS5A polymorphism is at one or more of positions M28, Q30, L31, and Y93.
[0238] In certain embodiments, at least one DAA comprises gleprevir and pibrentasvir or a salt thereof. In certain embodiments, at least one DAA comprises gleprevir administered at a dose of 100 mg and pibrentasvir administered at a dose of 40 mg. In certain embodiments, at least one DAA is three tablets each containing 100 mg gleprevir and 40 mg pibrentasvir, administered orally once daily.
[0239] In certain embodiments, at least one DAA comprises ombitasvir, paritaprevir, ritonavir and dasabuvir or a salt form thereof. In certain embodiments, at least one DAA comprises ombitasvir administered at a dose of 12.5 mg, paritaprevir administered at a dose of 75 mg, ritonavir administered at a dose of 50 mg, and dasabuvir administered at a dose of 250 mg. In certain embodiments, at least one DAA is two tablets each containing 12.5 mg ombitasvir, 75 mg paritaprevir, 50 mg ritonavir (administered orally once daily) and one tablet containing 250 mg dasabuvir (administered twice daily).
[0240] In certain embodiments, at least one DAA comprises ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin. In certain embodiments, at least one DAA comprises ombitasvir administered at a dose of 12.5 mg, paritaprevir administered at a dose of 75 mg, ritonavir administered at a dose of 50 mg, and ribavirin administered at a dose of 800 mg, 1000 mg, 1200 mg, or 1400 mg. In certain embodiments, at least one DAA is two tablets each containing 12.5 mg ombitasvir, 75 mg paritaprevir, 50 mg ritonavir (administered orally once daily), one tablet containing 250 mg dasabuvir (administered twice daily), and ribavirin administered at a dose of 800 mg, 1000 mg, 1200 mg, or 1400 mg.
[0241] In certain embodiments, at least one DAA comprises ibasivir and grazoprevir. In certain embodiments, at least one DAA comprises ibasivir administered at a dose of 50 mg and grazoprevir administered at a dose of 100 mg. In certain embodiments, at least one DAA is a tablet comprising 50 mg ibasivir and 100 mg grazoprevir, administered orally once daily.
[0242] In certain embodiments, at least one DAA comprises ibasivir, grazoprevir and ribavirin. In certain embodiments, at least one DAA comprises ibasivir administered at a dose of 50 mg, grazoprevir administered at a dose of 100 mg, and ribavirin administered at a dose of 800 mg, 1000 mg, 1200 mg or 1400 mg. In certain embodiments, at least one DAA is a tablet (orally administered once a day) comprising 50 mg ibasivir and 100 mg grazoprevir and ribavirin administered at a dose of 1000 mg, 1200 mg, or 1400 mg. In certain embodiments, HCV infected subjects are determined to be infected with HCV genotypes having one or more resistance-related polymorphisms. In certain embodiments, resistance-related polymorphisms are NS5A polymorphisms. In certain embodiments, NS5A polymorphisms are at one or more of positions M28, Q30, L31, and Y93.
[0243] The recommended dose of ribavirin is based on body weight. In certain embodiments, for subjects weighing less than 75 kg, the daily dose of ribavirin is 1000 mg. In certain embodiments, for subjects weighing 75 kg or more, the daily dose is 1200 mg ribavirin.
[0244] In certain embodiments, the daily dose is administered orally in two divided doses, one dose in the morning and one dose in the evening. In certain embodiments, ribavirin is provided as a capsule containing 200 mg ribavirin.
[0245] In certain embodiments, for subjects weighing less than 66 kg, the daily dose of ribavirin is 800 mg. In certain embodiments, for subjects weighing 66 to 80 kg, the daily dose of ribavirin is 1000 mg. In certain embodiments, for subjects weighing 81 to 105 kg, the daily dose of ribavirin is 1200 mg. In certain embodiments, for subjects weighing more than 105 kg, the daily dose of ribavirin is 1400 mg.
[0246] Administration of the compounds or pharmaceutical compositions provided herein may allow for a reduction in the dosage amount or frequency of at least one DAA administered to HCV-infected subjects. Reducing the amount or frequency of one or more DAAs administered may reduce side effects and / or improve subject compliance. Therefore, in certain embodiments, the dose of at least one DAA administered during treatment is lower than the dose when the DAA is administered alone. For example, at least one DAA may be administered at a dose that is 25% lower than when at least one DAA is administered alone. In certain embodiments, the dose of at least one DAA administered during treatment is administered at a frequency that is lower than when at least one DAA is administered alone. For example, at least one DAA may be administered once a week instead of once a day. In certain embodiments, the amount and frequency of at least one DAA administered is lower than when at least one DAA is administered alone.
[0247] In certain embodiments, the compounds provided herein and at least one DAA are administered in a single pharmaceutical composition, ie, the compounds and at least one DAA are co-formulated in a pharmaceutical composition. Suitable routes of administration include subcutaneous, intravenous, oral or intramuscular administration.
[0248] In certain embodiments, one or more additional therapeutic agents are administered to HCV infected subjects. In certain embodiments, one or more additional therapeutic agents include immunotherapy, immunomodulators, therapeutic vaccines, antifibrotic agents, anti-inflammatory agents, bronchodilators, mucolytics, antimuscarinics, antileukotrienes, cell adhesion inhibitors, antioxidants, cytokine agonists, cytokine antagonists, lung surfactants, antimicrobial agents, anticancer agents, RNAi agents, or cyclophilin inhibitors.
[0249] In certain embodiments, the one or more additional therapeutic agents may be selected from the group consisting of cofactor inhibitors, HCV structural protein inhibitors, cyclophilin inhibitors, entry inhibitors, TLR7 agonists, and interferons.
[0250] Although the purpose of most current therapies is to eliminate the use of interferon, in some HCV infected subjects, interferon treatment may be warranted. In certain embodiments, another therapeutic agent is selected from interferon, ribavirin and telaprevir. In certain embodiments, interferon is selected from interferon alpha-2a, interferon alpha-2b, interferon alpha con-1, pegylated interferon alpha-2b and pegylated interferon alpha-2a.
[0251] HCV infected subjects may experience abnormal liver function, which is evaluated by measuring one or more of bilirubin, albumin and prothrombin time. Liver inflammation is evaluated by measuring liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST). One or more abnormal levels of these markers may indicate abnormal liver function. In certain embodiments, provided herein are methods including normalizing liver function. In certain embodiments, provided herein are methods including normalizing liver enzyme levels.
[0252] In any of the methods provided herein, the compound can be present in a pharmaceutical composition.
[0253] The compounds provided herein can be used in therapy. In certain embodiments, the compounds are used to treat HCV infected subjects. In certain embodiments, the compounds used to treat HCV infected subjects can be used in any of the therapeutic methods described herein.
[0254] Administration of anti-miR-122 compounds to HCV infected subjects results in a decrease in serum cholesterol, and thus can be used alone or in addition to another efficacy indicator (e.g., a decrease in HCV RNA levels) as a biomarker for evaluating the activity of anti-miR-122 compounds provided herein. Therefore, the methods provided herein include administering a compound or pharmaceutical composition provided herein to an HCV infected subject, collecting a blood sample from the subject, and measuring cholesterol in the HCV infected subject's blood sample. The level of cholesterol can be used as an indicator of the activity of anti-miR-122 compounds in HCV infected subjects.
[0255] Some modifications
[0256] In certain embodiments, provided herein are compounds in which the characteristics of the conjugate moiety (e.g., linker or ligand) are modified in a manner that retains the desired properties of the compound (e.g., efficacy in reducing HCV RNA levels in HCV-infected subjects and lack of significant inhibition of the MRP2 transporter).
[0257] RG6650 and compounds containing RG7443 can be described by structure C:
[0258] L n -Connector-X1-Nm -X2-MO;
[0259] wherein each L is independently a ligand and n is 1 to 10; each N is independently a modified or unmodified nucleoside and m is 1 to 5; X1 is a phosphodiester bond or a phosphorothioate bond; X2 is a phosphodiester bond or a phosphorothioate bond; and MO is RG7443.
[0260] For example, RG6650 can be described by the following embodiment of Structure C:
[0261]
[0262] wherein MO is a modified oligonucleotide having the structure U S C S AC S AC S TC S C S (RG7443), wherein the nucleoside followed by no subscript is a β-D-deoxyribonucleoside, the nucleoside followed by the subscript "S" is an S-cEt nucleoside, and each internucleoside linkage is a phosphorothioate internucleoside linkage; wherein X1 is a phosphodiester linkage; m is 1; N is β-D-deoxyriboadenosine; X2 is a phosphodiester linkage; and wherein the conjugate moiety is attached to the 3' terminus of the modified oligonucleotide.
[0263] In certain embodiments, one or more ligands of structure C can be a ligand that, like the GalNAc moiety, promotes uptake in the liver. Such ligands include cholesterol and other ligands with affinity for asialoglycoprotein receptor (ASGPR), including but not limited to galactose or galactose derivatives. In certain embodiments, the ligand with affinity for ASGPR is N-acetylgalactosamine, galactose, galactosamine, N-formylgalactosamine, N-propionyl-galactosamine, N-n-butyrylgalactosamine or N-isobutyryl-galactosamine.
[0264] In certain embodiments, when n is greater than 1, the linker comprises a moiety capable of attaching more than one L to the remainder of the compound (i.e., to the modified oligonucleotide (MO), to X1-N m -X2-MO, connected to XN m -Y-MO, etc.) backbone. In some such embodiments, L of the compound (e.g., a compound of structure A, structure B, structure C, or structure D) n -The joint part comprises the structure E:
[0265]
[0266] wherein each L is independently a ligand; n is from 1 to 10; S is a backbone; and Q' and Q" are independently linking groups.
[0267] In certain embodiments, each Q' and Q" is independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20 Alkoxy, amino, amido, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, and 6-aminohexanoic acid.
[0268] In certain embodiments, the backbone attaches 2, 3, 4 or 5 ligands to a modified oligonucleotide. In certain embodiments, the backbone attaches 3 ligands to a modified oligonucleotide.
[0269] A non-limiting exemplary structure E is structure E(i):
[0270]
[0271] wherein L1, L2 and L3 are each independently a ligand; Q'1, Q'2, Q'3 and Q" are each independently a linking group; and R1, R2, R3 and R4 are each independently selected from H, C1-C6 alkyl and substituted C1-C6 alkyl.
[0272] In some embodiments, Q'1, Q'2, Q'3 and Q" are each independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20In some embodiments, R1, R2, R3 and R4 are each independently selected from: H, methyl, ethyl, propyl, isopropyl and butyl. In some embodiments, R1, R2, R3 and R4 are each selected from: H and methyl.
[0273] Another non-limiting exemplary Structure E is Structure E(ii):
[0274]
[0275] wherein L1, L2 and L3 are each independently a ligand; Q'1, Q'2, Q'3 and Q" are each independently a linking group; and R1 is selected from H, C1-C6 alkyl and substituted C1-C6 alkyl.
[0276] In some embodiments, Q'1, Q'2, Q'3 and Q" are each independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20 In some embodiments, R1 is selected from H, methyl, ethyl, propyl, isopropyl and butyl. In some embodiments, R1 is H or methyl.
[0277] Another non-limiting exemplary Structure E is Structure E(iii):
[0278]
[0279] wherein L1, L2 and L3 are each independently a ligand; Q'1, Q'2, Q'3 and Q" are each independently a linking group; and R1, R2, R3, R4 and R5 are each independently selected from H, C1-C6 alkyl and substituted C1-C6 alkyl.
[0280] In some embodiments, Q'1, Q'2, Q'3 and Q" are each independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20 In some embodiments, R1, R2, R3, R4 and R5 are each independently selected from: H, methyl, ethyl, propyl, isopropyl and butyl. In some embodiments, R1, R2, R3, R4 and R5 are each selected from: H and methyl.
[0281] Another non-limiting exemplary Structure E is Structure E(iv):
[0282]
[0283] wherein L1 and L2 are each independently a ligand; Q'1, Q'2 and Q" are each independently a linking group; and R1, R2 and R3 are each independently selected from H, C1-C6 alkyl and substituted C1-C6 alkyl.
[0284] In some embodiments, Q'1, Q'2 and Q" are each independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20 In some embodiments, R1, R2 and R3 are each independently selected from: H, methyl, ethyl, propyl, isopropyl and butyl. In some embodiments, R1, R2 and R3 are each selected from: H and methyl.
[0285] Another non-limiting exemplary structure E is structure E(v):
[0286]
[0287] wherein L1 and L2 are each independently a ligand; Q'1, Q'2 and Q" are each independently a linking group; and R1, R2 and R3 are each independently selected from H, C1-C6 alkyl and substituted C1-C6 alkyl.
[0288] In some embodiments, Q'1, Q'2 and Q" are each independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20 In some embodiments, R1, R2 and R3 are each independently selected from: H, methyl, ethyl, propyl, isopropyl and butyl. In some embodiments, R1, R2 and R3 are each selected from: H and methyl.
[0289] Another non-limiting exemplary Structure E is Structure E(vi):
[0290]
[0291] wherein L1, L2 and L3 are each independently a ligand; Q'1, Q'2, Q'3 and Q" are each independently a linking group; and R1, R2 and R3 are each independently selected from H, C1-C6 alkyl and substituted C1-C6 alkyl.
[0292] In some embodiments, Q'1, Q'2, Q'3 and Q" are each independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20In some embodiments, R1, R2 and R3 are each independently selected from: H, methyl, ethyl, propyl, isopropyl and butyl. In some embodiments, R1, R2 and R3 are each selected from: H and methyl.
[0293] Another non-limiting exemplary Structure E is Structure E(vii):
[0294]
[0295] wherein L1, L2 and L3 are each independently a ligand; Q'1, Q'2, Q'3 and Q" are each independently a linking group; and R1, R2 and R3 are each independently selected from H, C1-C6 alkyl and substituted C1-C6 alkyl; and Z and Z' are each independently selected from O and S.
[0296] In some embodiments, Q'1, Q'2, Q'3 and Q" are each independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20 Alkoxy, amino, amide, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), 4-(N-maleimidomethyl) cyclohexane-1-carboxylic acid succinimide ester and 6-aminocaproic acid. In some embodiments, R1, R2 and R3 are each independently selected from: H, methyl, ethyl, propyl, isopropyl and butyl. In some embodiments, R1, R2 and R3 are each selected from H and methyl. In some embodiments, Z or Z' on at least one P atom is S, and the other Z or Z' is O (i.e., phosphorothioate linkage). In some embodiments, each -OP(Z)(Z')O- is a phosphorothioate linkage. In some embodiments, Z and Z' on at least one P atom are both O (i.e., phosphodiester linkage). In some embodiments, each -OP(Z)(Z')O- is a phosphodiester linkage.
[0297] Another non-limiting exemplary Structure E is Structure E(viii):
[0298]
[0299] wherein L1, L2 and L3 are each independently a ligand; Q'1, Q'2, Q'3 and Q" are each independently a linking group; and R1, R2, R3 and R4 are each independently selected from H, C1-C6 alkyl and substituted C1-C6 alkyl.
[0300] In some embodiments, Q'1, Q'2, Q'3 and Q" are each independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20 In some embodiments, R1, R2, R3 and R4 are each independently selected from: H, methyl, ethyl, propyl, isopropyl and butyl. In some embodiments, R1, R2, R3 and R4 are each selected from: H and methyl.
[0301] For example, PCT Publication No. WO 2013 / 033230; U.S. Pat. No. 8,106,022 B2; U.S. Publication No. 2012 / 0157509 A1; U.S. Pat. No. 5,994,517; U.S. Pat. No. 7,491,805 B2; U.S. Pat. No. 8,313,772 B2; Manoharan, M., Chapter 16, Antisense Drug Technology, Crooke, ST, Marcel Dekker, Inc., 2001, 391-469 describes non-limiting exemplary backbones and / or linkers comprising the backbone and their synthesis.
[0302] In certain embodiments, the compound has L n -The joint part comprises the structure F:
[0303]
[0304] in:
[0305] B is selected from -O-, -S-, -N(R N )-, -ZP(Z')(Z”)O-, -ZP(Z')(Z”)ON m -X- and -ZP(Z')(Z")ON m -Y-;
[0306] MO is RG7443;
[0307] R N is selected from H, methyl, ethyl, propyl, isopropyl, butyl and benzyl;
[0308] Z, Z' and Z" are each independently selected from O and S;
[0309] Each N is independently a modified or unmodified nucleoside;
[0310] m is 1 to 5;
[0311] X is selected from the group consisting of a phosphodiester linkage and a phosphorothioate linkage;
[0312] Y is a phosphodiester linkage; and
[0313] The wavy line indicates connections to the linker and the rest of the ligand.
[0314] In certain embodiments, the wavy line indicates attachment to Structure E above.
[0315] In certain embodiments, n is 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5.
[0316] In certain embodiments, the compound has L n -The linker part comprises the structure G:
[0317]
[0318] in:
[0319] B is selected from -O-, -S-, -N(R N )-, -ZP(Z')(Z”)O-, -ZP(Z')(Z”)ON m -X- and -ZP(Z')(Z")ON m -Y-;
[0320] MO is RG7443;
[0321] R N is selected from H, methyl, ethyl, propyl, isopropyl, butyl and benzyl;
[0322] Z, Z' and Z" are each independently selected from O and S;
[0323] Each N is independently a modified or unmodified nucleoside;
[0324] m is 1 to 5;
[0325] X is selected from the group consisting of a phosphodiester linkage and a phosphorothioate linkage;
[0326] Y is a phosphodiester linkage;
[0327] Each L is independently a ligand; n is 1 to 10; S is a backbone; and Q' and Q" are independently linking groups.
[0328] In certain embodiments, each Q' and Q" is independently selected from the group consisting of: peptides, ethers, polyethylene glycols, alkyl groups, C1-C 20 Alkyl, substituted C1-C 20 Alkyl, C2-C 20 Alkenyl, substituted C2-C 20 Alkenyl, C2-C 20 Alkynyl, substituted C2-C 20 Alkynyl, C1-C 20 Alkoxy, substituted C1-C 20 Alkoxy, amino, amido, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, and 6-aminohexanoic acid.
[0329] A non-limiting exemplary compound L n - A linker moiety (e.g., having Structure F or Structure G) is shown below in Structure H:
[0330]
[0331] The wavy line indicates the connection to the modified oligonucleotide RG7443, such as X1 in structure B, or X or Y in structure C or structure D.
[0332] In certain embodiments, the compound comprising the conjugated modified oligonucleotide described herein has structure A:
[0333] L n - connector-MO;
[0334] wherein each L is independently a ligand and n is 1 to 10; and MO is RG7443.
[0335] In some embodiments, the compound has the structure:
[0336]
[0337] wherein each N is independently a modified or unmodified nucleoside and m is 1 to 5; X1 and X2 are each independently a phosphodiester linkage or a phosphorothioate linkage; and MO is RG7443.
[0338] In certain embodiments, at least one of X1 and X2 is a phosphodiester linkage. In certain embodiments, each of X1 and X2 is a phosphodiester linkage.
[0339] In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3, 4, or 5. In certain embodiments, m is 2, 3, 4, or 5. In certain embodiments, when m is greater than 1, N m Each modified or unmodified nucleoside of N can be linked to N via a phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage. m adjacent modified or unmodified nucleosides.
[0340] In any of the embodiments described herein, N m Can be N' p N", wherein each N' is independently a modified or unmodified nucleoside and p is 0 to 4; and N" is a nucleoside comprising an unmodified sugar moiety.
[0341] In certain embodiments, p is 0. In certain embodiments, p is 1, 2, 3, or 4. In certain embodiments, when p is 1, 2, 3, or 4, each N' comprises an unmodified sugar moiety.
[0342] In certain embodiments, the unmodified sugar moiety is β-D-ribose or β-D-deoxyribose.
[0343] In certain embodiments, when p is 1, 2, 3 or 4, N' comprises a purine nucleobase. In certain embodiments, N" comprises a purine nucleobase. In certain embodiments, the purine nucleobase is selected from adenine, guanine, hypoxanthine, xanthine and 7-methylguanine. In certain embodiments, N' is β-D-deoxyriboadenosine or β-D-deoxyriboguanosine. In certain embodiments, N" is β-D-deoxyriboadenosine or β-D-deoxyriboguanosine.
[0344] In certain embodiments, p is 1, N' and N" are each β-D-deoxyriboadenosine, and N' and N" are linked by a phosphodiester internucleoside linkage. In certain embodiments, p is 1, N' and N" are each β-D-deoxyriboadenosine, and N' and N" are linked by a phosphodiester internucleoside linkage. In certain embodiments, p is 1, N' and N" are each β-D-deoxyriboadenosine, and N' and N" are linked by a phosphothioate internucleoside linkage.
[0345] In certain embodiments, when p is 1, 2, 3 or 4, N' comprises a pyrimidine nucleobase. In certain embodiments, N" comprises a pyrimidine nucleobase. In certain embodiments, the pyrimidine nucleobase is selected from cytosine, 5-methylcytosine, thymine, uracil and 5,6-dihydrouracil.
[0346] In certain embodiments, the sugar moiety of each N is independently selected from β-D-ribose, β-D-deoxyribose, 2'-O-methoxy sugar, 2'-O-methyl sugar, 2'-fluoro sugar and bicyclic sugar moiety. In certain embodiments, each bicyclic sugar moiety is independently selected from cEt sugar moiety, LNA sugar moiety and ENA sugar moiety. In certain embodiments, the cEt sugar moiety is S-cEt sugar moiety. In certain embodiments, the cEt sugar moiety is R-cEt sugar moiety.
[0347] In certain embodiments, the compound comprises a conjugate portion connected to the 5' end of a modified oligonucleotide. In certain embodiments, the compound comprises a conjugate portion connected to the 3' end of a modified oligonucleotide. In certain embodiments, the compound comprises a conjugate portion connected to the 5' end of a modified oligonucleotide. In certain embodiments, the compound comprises a first conjugate portion connected to the 3' end of a modified oligonucleotide and a second conjugate portion connected to the 5' end of a modified oligonucleotide.
[0348] Certain metabolites
[0349] When exposed to exonucleases and / or endonucleases in vitro or in vivo, the compound may be subjected to cleavage at different positions of the entire compound. The product of this cleavage can retain a certain degree of activity of the parent compound, and is therefore considered as an active metabolite. Therefore, the metabolites of the compound can be used in the methods described herein. In certain embodiments, the modified oligonucleotide (unconjugated or conjugated) is subjected to cleavage on the 5' end and / or 3' end, thereby producing a metabolite with less than 1, 2 or 3 nucleotides on the 5' end and / or 3' end relative to the parent modified oligonucleotide. In certain embodiments, the modified oligonucleotide is subjected to cleavage on the 5' end, releasing the nucleotides at the 5'-end and producing a metabolite with less than 1 nucleotide on the 5' end relative to the parent modified oligonucleotide. In certain embodiments, the modified oligonucleotide is subjected to cleavage on the 5' end, releasing two 5'-terminal nucleosides and producing a metabolite with less than two nucleotides on the 5' end relative to the parent modified oligonucleotide. In certain embodiments, the modified oligonucleotide is subjected to cleavage on the 3' end, releasing the nucleotide at the 3'-terminus and producing a metabolite with one less nucleotide at the 3' end relative to the parent modified oligonucleotide. In certain embodiments, the modified oligonucleotide is subjected to cleavage on the 3' end, releasing two 3'-terminal nucleosides and producing a metabolite with two less nucleotides at the 3' end relative to the parent modified oligonucleotide.
[0350] Compounds comprising a modified oligonucleotide linked to a conjugate moiety may also be subjected to cleavage at a site within the linker between the modified oligonucleotide and the ligand. In certain embodiments, cleavage produces a parent modified oligonucleotide comprising a portion of the conjugate moiety. In certain embodiments, cleavage produces a parent modified oligonucleotide comprising one or more subunits of the linker between the modified oligonucleotide and the ligand. For example, in a compound having structure L n -Connector-X1-N m In the case of -X2-MO, in some embodiments, cleavage produces m In some embodiments, cleavage of the conjugated modified oligonucleotide produces the parent modified oligonucleotide. In some such embodiments, for example, in a compound having structure L n -Connector-X1-N m In the case of -X2-MO, in some embodiments, cleavage produces a product that does not contain N m The parent modified oligonucleotide of any nucleotide.
[0351] Certain nucleobase sequences
[0352] Any of the anti-miR-122 nucleobase sequences described herein (including but not limited to those found in the Examples and Sequence Listings) are independent of any modification of the nucleic acid. Thus, the nucleic acid defined by the SEQ ID NO may independently comprise one or more modifications to one or more sugar moieties, one or more internucleoside linkages and / or one or more nucleobases.
[0353] Although the sequence listing attached to this document identifies each nucleobase sequence as "RNA" or "DNA" as required, in fact those sequences can be modified with any combination of chemical modifications. Those skilled in the art will readily appreciate that the use of names such as "RNA" or "DNA" to describe modified oligonucleotides is somewhat arbitrary. For example, a modified oligonucleotide comprising a nucleoside containing a 2'-OH sugar moiety and a thymine base can be described as a DNA with a modified sugar (2'-OH for the natural 2'-H of DNA) or an RNA with a modified base (thymine (methylated uracil) for the natural uracil of RNA).
[0354] Therefore, the nucleic acid sequences provided herein (including but not limited to those in the sequence list) are intended to encompass nucleic acids containing any combination of natural or modified RNA and / or DNA, including but not limited to such nucleic acids with modified nucleobases. As an example and not limitation, a modified oligonucleotide with a nucleobase sequence of "ATCGATCG" encompasses any oligonucleotide with such a nucleobase sequence, whether modified or unmodified, including but not limited to such compounds containing RNA bases, such as those with the sequence "AUCGAUCG" and those with some DNA bases and some RNA bases such as "AUCGATCG" and bases with other modifications such as "ATCGATCG". me CGAUCG" oligonucleotide, wherein me C indicates 5-methylcytosine. Similarly, a modified oligonucleotide having a nucleobase sequence of "AUCGAUCG" encompasses any oligonucleotide having such a nucleobase sequence, whether modified or unmodified, including but not limited to such compounds comprising DNA bases, such as those having the sequence "ATCGATCG" and those having some DNA bases and some RNA bases such as "AUCGATCG" and having other modified bases such as "ATCGATCG". me CGAUCG" oligonucleotide, wherein me C indicates 5-methylcytosine.
[0355] Some modifications
[0356] Modified oligonucleotides may comprise one or more modifications to nucleobases, sugars and / or internucleoside linkages. Modified nucleobases, sugars and / or internucleoside linkages may be selected over unmodified forms for desirable properties such as enhanced cellular uptake, enhanced affinity for other oligonucleotides or nucleic acid targets, and increased stability in the presence of nucleases.
[0357] In certain embodiments, the modified oligonucleotide comprises one or more modified nucleosides. In certain embodiments, the modified nucleosides are stabilizing nucleosides. An example of a stabilizing nucleoside is a 2'-modified nucleoside.
[0358] In certain embodiments, a modified nucleoside comprises a modified sugar moiety. In certain embodiments, a modified nucleoside comprising a modified sugar moiety comprises an unmodified nucleobase. In certain embodiments, a modified sugar comprises a modified nucleobase. In certain embodiments, a modified nucleoside is a 2'-modified nucleoside.
[0359] In certain embodiments, the 2'-modified nucleoside comprises a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety is a D sugar in an α configuration. In certain such embodiments, the bicyclic sugar moiety is a D sugar in a β configuration. In certain such embodiments, the bicyclic sugar moiety is an L sugar in an α configuration. In certain such embodiments, the bicyclic sugar moiety is an L sugar in a β configuration.
[0360] In certain embodiments, the bicyclic sugar moiety comprises a bridging group between the 2' carbon atom and the 4' carbon atom. Nucleosides comprising a bicyclic sugar moiety are referred to as bicyclic nucleosides or BNAs. In certain embodiments, bicyclic nucleosides include but are not limited to (A) α-L-methyleneoxy (4'-CH2-O-2') BNA as described below; (B) β-D-methyleneoxy (4'-CH2-O-2') BNA; (C) ethyleneoxy (4'-(CH2)2-O-2') BNA; (D) aminooxy (4'-CH2-ON(R)-2') BNA; (E) oxyamino (4'-CH2-N(R)-O-2') BNA; (F) methyl (methylene) (4'-CH2-CH(CH3)-2')BNA; (J) c-MOE (4'-CH2-OMe-2')BNA and (K) propylene carbocycle (4'-(CH2)3-2')BNA.
[0361]
[0362] wherein Bx is a nucleobase moiety, and R is independently H, a protecting group or a C1-C 12 alkyl.
[0363] In certain embodiments, the 2'-modified nucleoside comprises a 2'-substituent selected from the group consisting of F, OCF3, O-CH3, OCH2CH2OCH3, 2'-O(CH2)2SCH3, O-(CH2)2-ON(CH3)2, -O(CH2)2O(CH2)2N(CH3)2, and O-CH2-C(=O)-N(H)CH3.
[0364] In certain embodiments, the 2'-modified nucleoside comprises a 2'-substituent selected from F, O-CH3, and OCH2CH2OCH3.
[0365] In certain embodiments, the modified oligonucleotide comprises one or more internucleoside modifications. In certain such embodiments, each internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage. In certain embodiments, the modified internucleoside linkage comprises a phosphorus atom.
[0366] In certain embodiments, the modified oligonucleotide comprises at least one phosphorothioate internucleoside linkage. In certain embodiments, each internucleoside linkage of the modified oligonucleotide is a phosphorothioate internucleoside linkage.
[0367] In certain embodiments, the modified oligonucleotide comprises one or more modified nucleobases. In certain embodiments, the modified nucleobase is selected from 7-deazaguanine, 7-deazaadenine, hypoxanthine, xanthine, 7-methylguanine, 2-aminopyridine and 2-pyridone. In certain embodiments, the modified nucleobase is selected from 5-substituted pyrimidine, 6-azapyrimidine and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
[0368] Some synthetic methods
[0369] Modified oligonucleotides can be prepared using automated solid phase synthesis methods known in the art. In the solid phase synthesis process, phosphoramidite monomers are coupled to nucleosides covalently attached to a solid support in sequence. This nucleoside is the 3' terminal nucleoside of the modified oligonucleotide. Typically, the coupling cycle includes four steps: trityl removal (removing the 5'-hydroxyl protecting group with acid), coupling (connecting the activated phosphoramidite to a carrier-bound nucleoside or oligonucleotide), oxidation or sulfurization (converting the newly formed phosphite triester with an oxidant or sulfurizing agent), and capping (acetylation of unreacted 5'-hydroxyl). After the last coupling cycle, the solid support-bound oligonucleotide is subjected to a trityl removal step, followed by a cleavage and deprotection step, which simultaneously releases the oligonucleotide from the solid support and removes the protecting group from the base. The solid support is removed by filtration, and the filtrate is concentrated and the resulting solution is tested for characteristics and purity. Then, for example, a column filled with an anion exchange resin is used to purify the oligonucleotide.
[0370] The modified oligonucleotide of GalNAc conjugation can be prepared using an automatic solid phase synthesis similar to the solid phase synthesis producing unconjugated oligonucleotide. In the process of synthesizing the oligonucleotide of GalNAc conjugation, the phosphoramidite monomer is coupled with the GalNAc conjugate covalently attached to the solid support in sequence. The synthesis of GalNAc conjugate and GalNAc conjugate solid support is described in, for example, U.S. Patent No. 8,106,022 and International Application Publication No. WO 2013 / 033230, in order to describe the synthesis of the conjugate containing carbohydrate (including the conjugate comprising one or more GalNAc parts) and the synthesis of the conjugate covalently attached to the solid support, each of the references is incorporated herein by reference in its entirety.
[0371] Certain pharmaceutical compositions
[0372] Provided herein are pharmaceutical compositions comprising a compound provided herein and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is an aqueous solution. In certain embodiments, the aqueous solution is a saline solution. As used herein, a pharmaceutically acceptable diluent is understood to be a sterile diluent. Suitable routes of administration include, but are not limited to, intravenous and subcutaneous administration.
[0373] In certain embodiments, the pharmaceutical composition is a compound provided herein, which is prepared in a suitable diluent, adjusted to pH 7.0-9.0 with an acid or base during preparation, and then lyophilized under sterile conditions. The lyophilized modified oligonucleotide is then reconstituted with a suitable diluent (e.g., an aqueous solution, such as water) or a physiologically compatible buffer (e.g., a saline solution, Hanks's solution or Ringer's solution). The reconstituted product is administered in the form of subcutaneous injection or intravenous infusion. The lyophilized drug can be packaged in a 2 mL type I transparent glass bottle (treated with ammonium sulfate), plugged with a bromobutyl rubber seal, and sealed with an aluminum top seal.
[0374] In certain embodiments, the pharmaceutical composition is administered in the form of a dosage unit (eg, tablet, capsule, bolus, etc.). In some embodiments, the pharmaceutical composition comprises a compound provided herein at a dose within a range selected from: 25 mg to 250 mg. In certain embodiments, the pharmaceutical composition comprises a compound provided herein in a dose selected from 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, or 250 mg.
[0375] The pharmaceutical composition may also contain suitable stabilizers or agents which increase the solubility of the pharmaceutical agent to allow for the preparation of highly concentrated solutions.
[0376] In certain embodiments, the pharmaceutical compositions provided herein may additionally contain other auxiliary components that are usually present in pharmaceutical compositions, and their usage amounts are the amounts determined in the art. Thus, for example, the compositions may contain additional compatible pharmaceutical active substances, such as antipruritic agents, astringents, local anesthetics or anti-inflammatory agents.
[0377] Some miR-122 kits
[0378] The present invention also provides a medicine box. In some embodiments, the medicine box comprises one or more compounds provided herein. In some embodiments, the compound provided herein is present in a vial. In a distribution package, for example, multiple vials, such as 10, can be provided. In some embodiments, the vial is made accessible with a syringe. The medicine box may also include instructions for use of the compound provided herein.
[0379] In some embodiments, the medicine box can be used to administer the compound provided herein to a subject. In such cases, in addition to comprising at least one compound provided herein, the medicine box may also include one or more of the following: a syringe, an alcohol swab, a cotton ball, and / or a gauze pad. In some embodiments, the compound complementary to miR-122 may be present in a pre-filled syringe (such as a single-dose syringe with a 27-gauge, 1 / 2-inch needle, for example, with a needle protector), rather than in a vial. In, for example, a plurality of pre-filled syringes, such as 10, may be present in a distribution package. The medicine box may also include instructions for administration of the compound provided herein.
[0380] Some experimental models
[0381] In certain embodiments, the present invention provides methods of using and / or testing compounds provided herein in experimental models. One skilled in the art is able to select and modify the protocol for the experimental model to evaluate the compounds provided herein.
[0382] The effect of antisense inhibition of microRNA after administration of anti-miR compounds can be evaluated by various methods known in the art. In certain embodiments, the method is used to quantify microRNA levels in cells or tissues in vitro or in vivo. In certain embodiments, changes in microRNA levels are measured by microarray analysis. In certain embodiments, one of several commercially available PCR assays such as MicroRNA assay (Applied Biosystems, Life Technologies brand) was used to measure changes in microRNA levels.
[0383] Can use luciferase cell culture assay to assess the in vitro activity of anti-miR compounds.In this assay, microRNA luciferase sensor construct is engineered to contain one or more binding sites of the related microRNA fused to the luciferase gene.When microRNA binds to its homologous site in the luciferase sensor construct, luciferase expression is suppressed.When suitable anti-miR is introduced into the cell, it binds to the target microRNA and releases the suppression of luciferase expression.Therefore, in this assay, anti-miR as an effective inhibitor of related microRNA will cause luciferase expression to increase.
[0384] The activity of anti-miR compounds can be assessed by measuring the mRNA and / or protein levels of the targets of microRNAs. MicroRNAs bind to complementary sites in one or more target RNAs, causing the target RNAs to be suppressed, thereby inhibiting the microRNAs to cause the levels of mRNAs and / or proteins of the targets of the microRNAs to increase (i.e., derepression). The derepression of one or more target RNAs can be measured in vivo or in vitro. For example, the target of miR-122 is aldolase A (ALDOA). Inhibition of miR-122 causes an increase in the level of ALDOA mRNA, so the ALDOA mRNA level can be used to assess the inhibitory activity of anti-miR-122 compounds.
[0385] The effect of anti-miR-122 compounds on HCV replication can be measured in HCV replicon assays. In this assay, the compound is introduced into a cell line (e.g., a human hepatocellular carcinoma cell line) comprising a subgenomic replicon of HCV with a stable luciferase reporter and three cell culture adaptation mutations (luc-ubi-neo / ET). The luciferase reporter is used as an indirect indicator of HCV replication. The replicon used can be a parent HCV genotype or an HCV genotype with a mutation that imparts antiviral resistance. Anti-miR-122 compounds can be assessed individually or in combination with other agents for the treatment of HCV infection. In some embodiments, modified oligonucleotides can be tested in vivo or in vitro assays, and subsequently conjugated to form a compound used in the method described herein.
[0386] Example
[0387] The following examples are presented to more fully illustrate some embodiments of the present invention. However, the examples should not be construed as limiting the broad scope of the present invention. Those skilled in the art will be prone to designing various compounds using the basic principles of this discovery without departing from the spirit of the present invention.
[0388] Example 1: Anti-miR-122 compounds for treating HCV infection
[0389] miR-122 is a microRNA specifically expressed in large amounts in the liver and is a key host factor for the accumulation of hepatitis C virus (Jopling et al., Science. 2005, 309 (5740), 1577-81). miR-122 interacts with HCV by binding to two closely spaced seed sequence sites in the 5' non-coding region of the HCV genome, resulting in HCV genome stabilization, supporting replication and translation (Jangra et al., J Virol., 2010, 84: 6615-6625; Machlin et al., 2011). RG-101 is a GalNAc-conjugated modified oligonucleotide targeting miR-122.
[0390] In a completed Phase I human proof-of-concept study, treatment with a single subcutaneous dose of RG-101 as monotherapy resulted in significant and sustained reductions in viral load in all treated HCV-infected subjects, including those with refractory genotypes, various liver fibrosis states, and those experiencing viral relapse after a prior IFN-containing regimen.
[0391] In a completed Phase II study evaluating RG-101 in combination with multiple approved direct-acting antivirals (DAAs), subjects received a single subcutaneous injection of RG-101 at 2 mg / kg on day 1, followed by 28 days of once-daily oral DAAs ( or Daklinza TM ), followed by an additional subcutaneous injection of 2 mg / kg of RG-101 on day 29. Viral response was defined as HCV RNA viral load below the lower limit of quantification (LLOQ) using a real-time HCV assay (Abbott), and LLOQ = 12 IU / mL. The number and percentage of subjects with viral response are shown in Table 1. Notably, all subjects in the RG-101+Harvoni group experienced a significant and sustained decrease in viral load over the 48-week follow-up period. Six and four subjects relapsed in the RG-101+Olysio and RG-101+Daklinza groups, respectively. In the RG-101+Olysio group, one subject withdrew consent and was therefore not included in the 48-week time point.
[0392] Table 1: Viral responses after treatment with RG-101 + DAA
[0393]
[0394] In the Phase 2 study, 10 of 200 subjects experienced transient hyperbilirubinemia, characterized by increases in conjugated and total bilirubin above the upper limit of normal (ULN). The U.S. Food and Drug Administration has placed a clinical hold on the IND for RG-101 for the treatment of chronic HCV infection.
[0395] To identify potential mechanisms of hyperbilirubinemia, a literature search was performed and preclinical data from RG-101 studies were thoroughly reanalyzed. The literature search revealed no previously reported associations between miR-122 and the bilirubin metabolic pathway or between oligonucleotides as a class of drugs and the bilirubin metabolic pathway. In a large number of studies in mice, rats, and monkeys, no cases of increased bilirubin were identified at doses significantly higher than the clinical doses tested. In addition, in the pre-IND phase, RG-101 and its active metabolites were tested for their ability to interact with cytochrome P450 enzymes and uptake and efflux transporters. As expected for oligonucleotides, neither compound was able to significantly interact with the enzymes and transporters.
[0396] It is hypothesized that interference with the bilirubin transporter in the liver can lead to hyperbilirubinemia. There are several transporters in the liver that are involved in the transport of bilirubin between hepatocytes and bile. One of the transporters, multidrug resistance-associated protein 2 (MRP2), is encoded by the ABCC2 gene and is expressed on the apical side of hepatocytes, the apical membrane of proximal tubular cells, and the intestinal lumen (enterocytes). The MRP2 transporter is involved in the release of organic anions such as conjugated bilirubin. Known inhibitors of the MRP2 transporter include probenecid, furosemide, ritonavir, abacavir, cyclosporin A, and tenofovir. However, as mentioned above, oligonucleotides have not been previously reported as inhibitors of MRP2.
[0397] Another factor leading to hyperbilirubinemia may be the expression level of MRP2 in HCV-infected subjects. MRP2 expression in HCV-infected subjects was reduced by approximately 70% compared to uninfected subjects (J Hepatol. 2001 Dec; 35(6): 765-73). Therefore, HCV-infected subjects may be more susceptible to compounds that inhibit the activity of the MRP2 transporter because the level of MRP2 in the subject has been reduced. In addition, the expression of MRP2 in humans is lower than that in rodents and non-human primates, which may explain why hyperbilirubinemia was not observed in preclinical or IND-enabling studies.
[0398] To test the hypothesis that RG-101 interferes with the activity of the MRP2 transporter, an in vitro assay was performed according to methods known in the art (e.g., see Vermeer et al., Drug Metab. Dispos., 2016, 44(3): 453-9). In this assay, vesicles expressing efflux transporters are used to assess whether a drug is a substrate or inhibitor of the transporter. Inside-out vesicles are prepared from insect cells transiently transfected with a single efflux transporter, in this case MRP2. Since the vesicles are in an inside-out orientation, the MRP2 transporter pumps the radiolabeled substrate [3H]-estradiol-17β-glucuronide into the vesicles in an ATP-dependent manner, and the accumulation of the radiolabeled substrate within the vesicles is measured. If the compound is an inhibitor of MRP2 transport, the accumulation of the radiolabeled substrate will be reduced relative to the control sample. The inhibitory effect of the compound is assessed by determining the IC50, which is the concentration that results in a 50% inhibition of transporter-mediated uptake of the radiolabeled substrate.
[0399] RG-101 was subjected to an in vitro MRP2 assay. Both RG-101 and RG1649 (unconjugated anti-miR of RG-101) were tested at concentrations of 0, 0.1, 0.3, 1, 3, 10, 30, and 100 uM. The calculated IC50 values for RG-101 and RG1649 were 5.98 uM and 2.21 uM, respectively. Therefore, RG-101 inhibits the MPR2 transporter in this assay. Additional studies were performed and confirmed that both RG-101 and RG1649 inhibited the MRP2 transporter in this assay (RG-101 IC50 ranged from 5 to 62 uM; RG1649 IC50 ranged from 2 to 11 uM.
[0400] Although other HCV-infected subject-specific contributing factors cannot be definitively ruled out based in part on the MRP2 assay data, it is believed that a combination of factors including inhibition of conjugated bilirubin transport by RG-101, impaired baseline bilirubin transport in HCV-infected subjects, and preferential uptake of RG-101 by hepatocytes (due to the GalNAc conjugate moiety) may contribute to the observed hyperbilirubinemia. With this in mind, a screen was performed for alternative compounds targeting miR-122 that retained potent HCV antiviral activity but did not significantly interfere with bilirubin transport by the MRP2 transporter.
[0401] Example 2: In vitro screening of potent anti-miR-122 compounds lacking significant MRP2 inhibition
[0402] Anti-miR-122 compounds were selected for testing to evaluate HCV replicon inhibition, MRP2 transporter inhibition, in vitro and in vivo safety, in vivo efficacy, and in vivo efficacy in a mouse model of HCV infection. The compounds varied in length, nucleoside sugar modifications, and internucleoside linkage modifications. In addition, unconjugated compounds and GalNAc-conjugated compounds were also tested.
[0403] HCV replicon studies
[0404] HCV replicon assay is used to measure the ability of anti-miR-122 compounds to inhibit HCV genotype 1b replication. In this assay, the test compound is introduced into Huh7 cells stably transfected with HCV GT1b replicon containing luciferase reporter gene. Luciferase reporter is used as an indirect measurement of HCV replication. Although it is expected that the compound conjugated with GalNAc is better for the treatment of HCV infection, some unconjugated compounds are tested due to enhanced delivery to hepatocytes.
[0405] Selected compounds were tested at nine concentrations ranging from 0.015uM to 100uM. GS-7977 (sofosbuvir) was included as a positive control. Cells were plated in 96-well plates at a density of 8,000 cells per well. Compounds were added to the cells for a period of 72 hours. The luminescent signal in the supernatant was detected with Bright-Glo reagent and used to calculate the antiviral activity of each compound. CellTiter-Fluor reagent was used to evaluate cell viability. EC was calculated 50 (Concentration at which 50% inhibition was observed).
[0406] Some of the anti-miR-122 compounds tested in the replicon assay and their calculated EC50 values are shown in Table 2. Nucleosides without a subscript represent β-D-deoxyribonucleosides; nucleosides followed by a subscript "E" represent 2'-MOE nucleosides; nucleosides followed by a subscript "S" represent S-cEt nucleosides. Phosphodiester linkages are represented by "PO"; all other linkages are phosphorothioates. "Me" represents the 5-methyl group on the nucleoside base.
[0407] As shown in Table 2, changes in length, nucleoside sugar modifications, and / or internucleoside linkages result in differences in viral inhibition. For example, RG3054 contains an additional nucleoside at the 5' end relative to RG2634, yet RG3054 is far less potent than RG2634. RG6371 and RG6370 differ only in the number of phosphodiester and phosphorothioate internucleoside linkages, but exhibit different efficacy. Among the GalNAc-conjugated compounds, RG6650 and RG2634 were the most potent in this assay. Although RG6234 and RG497998 were potent in in vitro assays as unconjugated compounds, in vivo efficacy is not expected to be suitable for use as therapeutic agents.
[0408] Some compounds were tested in multiple experiments. The EC50 range for RG-101 was 1.994 to 10.68uM. The EC50 range for RG2634 was 13.93 to 31.1uM. The EC50 range for RG6650 was 7.716 to 11.3uM. The EC50 range for RG497998 was 7.708 to 10.87uM.
[0409] Table 2: Anti-miR-122 compounds in HCV replicon assay
[0410]
[0411]
[0412] The anti-miR-122 compounds selected based on efficacy and structural diversity in the HCV replicon assay were subjected to the MRP2 assay. As shown in Table 3, RG-101 and RG1649 inhibited MRP2 transporter activity in this assay. RG6650, RG2634, RG3054, RG6370, RG6234, and RG497998 each showed an IC greater than 100 uM. 50 , indicating that the compound does not significantly interfere with MRP2 transporter activity in this assay.
[0413] For some compounds, the assay was performed multiple times. The RG1649 IC50 ranged from 2 to 11 uM, and the RG-101 IC50 ranged from 5 to 62. Each time the compound was tested, the RG6650 was greater than 100 uM.
[0414] Table 3: Anti-miR-122 compounds in MRP2 transporter assay
[0415]
[0416]
[0417] Example 3: In vivo screening of potent anti-miR-122 compounds lacking MRP2 inhibition
[0418] Compounds that inhibit HCV replication in the replicon assay, but do not inhibit MRP2 in the in vitro transporter assay, were further tested for in vivo efficacy and safety.
[0419] effect
[0420] To determine in vivo efficacy, the compounds were evaluated for their ability to derepress the expression of liver aldolase A (ALDOA), a gene normally inhibited by miR-122 activity. Inhibition of miR-122 results in increased ALDOA expression, and thus ALDOA mRNA levels can be used to measure the inhibitory activity of miR-122 in vivo.
[0421] Only GalNAc-conjugated compounds were tested in this assay. Compounds were administered at molar equivalents of the anti-miR portion of the compound. A single subcutaneous dose of RG-101 was administered at a dose ranging from 0.004 to 1.116 umol / kg. The other compounds were administered as a single subcutaneous dose at a dose ranging from 0.006 to 1.942 umol / kg. After 7 days, the study was terminated. Liver tissue was collected for measurement of ALDOA mRNA and drug levels. Kidney tissue was collected for measurement of drug levels. Blood was collected for measurement of cholesterol.
[0422] ALDOA mRNA levels were measured in RNA isolated from the liver by quantitative PCR. The ED50 (umol / kg) of each compound was calculated using the fold change in ALDOA mRNA relative to saline ("ND" means "not determined"), as shown in Table 4.
[0423] With the exception of RG6370 (and RG3054, results uninterpretable), each compound tested in this assay showed an ED50 similar to RG-101 for ALDOA derepression (Table 4). For cholesterol reduction (Table 5), each compound tested showed an ED50 similar to or better than RG-101.
[0424] Table 4: ALDOA derepression
[0425]
[0426] *Results cannot be interpreted
[0427] Table 5: Cholesterol reduction
[0428]
[0429] Security
[0430] The safety of compounds that met the in vivo efficacy criteria was also tested. The ability of the compounds to trigger a pro-inflammatory response was evaluated by measuring the expression of the interferon-induced gene IFIT in the liver. In addition, ALT levels after administration of the compounds were also measured. Compounds RG6370 and RG3054 increased the expression of IFIT, indicating a potential pro-inflammatory response.
[0431] Based on the HCV replicon assay, MRP2 assay, and in vivo efficacy and safety studies, two compounds, RG6650 and RG2634, met the criteria established for the selection of appropriately potent and safe compounds.
[0432] The beginning of action
[0433] To determine whether RG6650 and RG2634 can be distinguished by the onset of action, groups of mice were treated with compounds at doses ranging from 0.014 to 1.117 umol / kg. Liver tissue was collected from groups of 4 to 5 mice 1, 3, 7, or 14 days after administration. RNA was isolated and ALDOA mRNA was measured. It was observed that RG6650 exhibited enhanced derepression of ALDOA mRNA at lower doses and earlier time points relative to RG2634, indicating that its onset of action was more rapid as measured by ALDOA mRNA derepression.
[0434] Example 4: Reduction of HCV RNA levels in response to miR-122 inhibition
[0435] Due to host-pathogen specificity, HCV can only infect humans and chimpanzees. Therefore, smaller species (such as mice) that are commonly used for in vivo experimental studies cannot be infected with HCV for testing candidate agents for treating HCV infection. To solve this problem, a human liver chimeric mouse model can be used (e.g., see Bissig et al., Proc Natl Acad Sci USA, 2007, 104: 20507-20511; Bissig et al., J Clin Invest., 2010, 120: 924-930). In this model, the liver of an immunodeficient mouse is repopulated with human hepatocytes to produce a chimeric liver in which most of the hepatocytes are human hepatocytes. The mice are then infected with HCV and treated with anti-HCV agents. This mouse model can be purchased from, for example, PhoenixBio.
[0436] Treatment of HCV-infected human chimeric liver mice
[0437] Anti-miR-122 compounds were tested in a human chimeric liver mouse model of HCV infection. The livers of immunodeficient mice were repopulated with human hepatocytes, generating chimeric livers in which the majority of hepatocytes were human. Baseline viral titers were obtained for each animal included in the study 6 weeks after inoculation with HCV genotype 1a.
[0438] Four animals per group were treated with PBS at a dose of 45 mg / kg, RG-101, or RG6650 at a dose of 60 mg / kg. Blood was collected on days 3, 7, 10, 14, 21, 28, 35, 42, and 49. The study was terminated on day 49.
[0439] like Figure 1 As shown, treatment with RG-101 and RG6650 resulted in a significant reduction in viral titers as measured by serum HCV RNA. RG6650 treatment resulted in a greater than 2 log reduction in serum HCV RNA in HCV infected animals.
[0440] The results showed that after a single administration of GalNAc-conjugated modified oligonucleotide RG6650, the HCV viral titer in HCV-infected animals was significantly reduced, and the effect was early and sustained.
[0441] As described herein, RG6650 is a potent inhibitor of HCV replication and, importantly, does not substantially interfere with MRP2 transporter activity in vitro. Thus, RG6650 has been identified as a candidate therapeutic agent for treating HCV infection.
[0442] Pharmacodynamic activity of anti-miR-122 compounds after oral administration
[0443] Experiments were performed to determine whether oral administration of RG6650 would result in pharmacodynamic modulation of miR-122 in the liver. RG7443, an unconjugated anti-miR of RG6650, was also tested. Although unconjugated anti-miR-122 was not as effective as GalNAc-conjugated anti-miR-122 in inhibiting miR-122 in HCV treatment, it was included in the oral administration study for comparison.
[0444] Five mice per group were treated with RG6650 or RG7443, as shown in Tables 6 and 7, where "sc" indicates subcutaneous administration and "po" indicates oral administration. Anti-miR compounds were delivered in PBS for subcutaneous administration. Anti-miR compounds for oral administration were prepared in PBS solution, and 0.3 M sodium bicarbonate (BC) was added to a pH of 9.5. For oral administration, the animals were fasted for 12 hours. For all treatment groups, mice were administered a single dose and sacrificed four days later. Liver tissue was collected for pharmacodynamic and pharmacokinetic analysis. RNA was isolated from the liver and kidney. ALDOA reduction in the liver was measured.
[0445] Table 6: PD effects after oral or subcutaneous administration of anti-miRs
[0446]
[0447]
[0448] Table 7: Anti-miR levels in liver tissue after oral or subcutaneous administration
[0449]
[0450] For RG6650 in the liver (*), results were not quantifiable in all but one animal, therefore data from only one animal are reported.
[0451] Subcutaneous administration of unconjugated and GalNAc-conjugated anti-miR-122 compounds resulted in derepression of ALDOA in the liver. Although oral administration of the unconjugated anti-miR-122 compound RG7443 did not produce a significant PD effect in the liver, oral administration of the GalNAc-conjugated compound RG6650 produced a PD effect comparable to that observed after subcutaneous administration. The data indicate that the GalNAc-conjugated anti-miR-122 compound RG6650 is an effective inhibitor of miR-122 after oral and subcutaneous administration.
[0452] Unrestricted uptake of anti-miR-122 compounds in primary human hepatocytes
[0453] To further compare the activity of RG-101, RG6650, and RG7443, primary human hepatocytes (PPH) were treated with each compound. Since ASGPR expression was downregulated in PHH after tiling, 3D PHH spheroids were formed using CCL-163 feeder cells and CellAble plates (ToyoGosei Co., Japan). After tiling on feeder cells for 4 days, PPHs were treated with the following doses of anti-miR: 0.0001nM, 0.001nM, 0.01nM, 0.1nM, 1nM, 10nM, or 100nM. The control group was treated with PBS. Three days later, cells were harvested, RNA was isolated, and ALDOA levels were measured by RT-PCR. The EC50 of each compound was calculated. The EC50 of RG-101, RG660, and RG7443 were 6.0nM, 2.07nM, and 1.91μM, respectively. The activity of the GalNAc-conjugated 9-mer was comparable to that of RG-101, indicating that HCV titers were clinically effectively reduced. In addition, the GalNAc conjugate significantly enhanced the activity of the 9-mer anti-miR-122, as indicated by an approximately 1000-fold reduction in EC50 (2.07 nM for RG6650 and 1.91 μM for RG7443). Thus, in primary human hepatocytes, the GalNAc-conjugated anti-miR-122 was significantly more active than the unconjugated anti-miR-122 at lower doses.
[0454] Various modifications of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description. It is intended that such modifications also fall within the scope of the appended claims. Each reference cited in this application (including but not limited to journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, Deposit Number, etc.) are expressly incorporated herein by reference in their entirety. Sequence Listing <110> REGULUS THERAPEUTICS INC. <120> GALNAC-conjugated modified oligonucleotides as MIR-122 inhibitors with HCV antiviral activity and reduced hyperbilirubinemia side effects <130> <150> US 62 / 668,467 <151> 2018-05-08 <160> 2 <170> PatentIn version 3.5 <210> 1 <211> twenty two <212> RNA <213> Homo sapiens <400> 1 uggaguguga caaugguguu ug 22 <210> 2 <211> 18 <212> DNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_features <222> (10)..(10) <223> RNA <400> 2 acaccattgu cacactcc 18
Claims
1. A compound having the following structure: , or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, which is a pharmaceutically acceptable salt having the structure.
3. The compound of claim 2, which is a sodium salt having the structure.
4. A pharmaceutical composition comprising the compound according to any one of claims 1 to 3 and a pharmaceutically acceptable diluent.
5. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable diluent is an aqueous solution.
6. The pharmaceutical composition of claim 5, wherein the aqueous solution is a saline solution.
7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 3, which is a lyophilized composition.
8. A pharmaceutical composition consisting of a compound as claimed in any one of claims 1 to 3 in saline solution.
9. An in vitro method for inhibiting miR-122 activity in a cell, the method comprising contacting the cell with a compound as claimed in any one of claims 1 to 3.
10. Use of a compound as claimed in any one of claims 1 to 3 or a pharmaceutical composition as claimed in any one of claims 4 to 8 in the preparation of a medicament for treating hepatitis C virus (HCV) infection in a subject.
11. Use of a compound as described in any one of claims 1 to 3 or a pharmaceutical composition as described in any one of claims 4 to 8 in the preparation of a medicament for treating HCV infection, wherein the medicament is administered together with at least one direct-acting antiviral drug (DAA) during a treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a starting dose of the medicament is administered at the beginning of the treatment period and a terminating dose of the medicament is administered at the end of the treatment period.
12. The use of claim 11, wherein the starting dose and the ending dose are the only doses of the drug administered during the treatment period.
13. Use of a compound as described in any one of claims 1 to 3 or a pharmaceutical composition as described in any one of claims 4 to 8 in the preparation of a medicament for treating HCV infection, wherein the medicament is administered together with at least one direct-acting antiviral drug (DAA) during the treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a starting dose of the medicament is administered at the beginning of the treatment period, and the starting dose is the only dose of the medicament administered during the treatment period.
14. Use of a compound as described in any one of claims 1 to 3 or a pharmaceutical composition as described in any one of claims 4 to 8 in the preparation of a medicament for treating HCV infection, wherein the medicament is administered together with at least one direct-acting antiviral drug (DAA) during a treatment period, wherein the duration of the treatment period is 12 weeks or less, and wherein a termination dose of the medicament is administered at the end of the treatment period, and the termination dose is the only dose of the medicament administered during the treatment period.
15. The use of any one of claims 11 to 14, wherein the duration of the treatment period is 2 to 10 weeks, 4 to 8 weeks, 2 to 6 weeks or 1 to 4 weeks.
16. The use of any one of claims 11 to 14, wherein the duration of the treatment period is 11 weeks, 10 weeks, 9 weeks, 8 weeks, 7 weeks, 6 weeks, 5 weeks, 4 weeks, 3 weeks, 2 weeks or 1 week.
17. The use according to any one of claims 11 to 14, wherein the duration of the treatment period is 26, 27, 28, 29 or 30 days.
18. The use according to any one of claims 11 to 14, wherein the duration of the treatment period is 28 or 29 days.
19. The use according to any one of claims 11 to 14, wherein the duration of the treatment period is 18, 19, 20, 21 or 22 days.
20. The use according to any one of claims 11 to 14, wherein the duration of the treatment period is 21 or 22 days.
21. The use of any one of claims 11 to 14, wherein the duration of the treatment period is 12, 13, 14, 15 or 16 days.
22. The use according to any one of claims 11 to 14, wherein the duration of the treatment period is 14 or 15 days.
23. The use according to any one of claims 11 to 14, wherein the duration of the treatment period is 6, 7, 8 or 9 days.
24. The use according to any one of claims 11 to 14, wherein the duration of the treatment period is 7 or 8 days.
25. The use of any one of claims 11 to 13, wherein the starting dose of the drug and the first dose of the DAA are administered within 7 days of each other.
26. The use of any one of claims 11 to 13, wherein the starting dose of the drug is administered one day prior to the first dose of the DAA.
27. The use of any one of claims 11 to 13, wherein the starting dose of the drug is administered on the same day as the first dose of the DAA.
28. The use of any one of claims 11 to 13, wherein the starting dose of the drug is administered one day after the first dose of the DAA.
29. The use of any one of claims 11, 12 or 14, wherein the final dose of the drug and the last dose of the DAA are administered within 7 days of each other.
30. The use of any one of claims 11, 12 or 14, wherein the termination dose of the drug is administered one day prior to the last dose of the DAA.
31. The use of any one of claims 11, 12 or 14, wherein the terminal dose of the drug is administered on the same day as the last dose of the DAA.
32. The use of any one of claims 11, 12 or 14, wherein the termination dose of the drug is administered one day after the last dose of the DAA.
33. The use of any one of claims 10 to 14, wherein the HCV infected subject is infected with genotype 1.
34. The use of claim 33, wherein the HCV infected subject is infected with genotype 1a.
35. The use of claim 33, wherein the HCV infected subject is infected with genotype 1b.
36. The use of any one of claims 10 to 14, wherein the HCV infected subject is infected with genotype 2.
37. The use of any one of claims 10 to 14, wherein the HCV infected subject is infected with genotype 3.
38. The use of any one of claims 10 to 14, wherein the HCV infected subject is infected with genotype 4.
39. The use of any one of claims 10 to 14, wherein the HCV infected subject is infected with genotype 5.
40. The use of any one of claims 10 to 14, wherein the HCV infected subject is infected with genotype 6.
41. The use of any one of claims 10 to 14, wherein the HCV infected subject is determined to be infected with HCV having one or more resistance associated polymorphisms.
42. The use of any one of claims 10 to 14, wherein the HCV infected subject is an untreated subject.
43. The use of any one of claims 10 to 14, wherein the HCV infected subject suffers from an HCV-related disease.
44. The use according to claim 43, wherein the HCV-related disease is cirrhosis, liver fibrosis, steatohepatitis, steatosis or hepatocellular carcinoma.
45. The use of any one of claims 10 to 14, wherein the HCV infected subject is an HCV infected subject with renal impairment.
46. The use of any one of claims 10 to 14, wherein the HCV infected subject is a HCV / HIV co-infected subject.
47. The use of any one of claims 10 to 14, wherein the administration achieves a sustained viral response.
48. The use of any one of claims 10 to 14, wherein the HCV RNA level is below the lower limit of quantification (LLOQ) at the end of the treatment period or at a time point after the end of the treatment period.
49. The use of claim 48, wherein the HCV RNA level is below the LLOQ 4 weeks after the end of the treatment period.
50. The use of claim 48, wherein the HCV RNA level is below the LLOQ 8 weeks after the end of the treatment period.
51. The use of claim 48, wherein the HCV RNA level is below the LLOQ 12 weeks after the end of the treatment period.
52. The use of claim 48, wherein the HCV RNA level is below the LLOQ 24 weeks after the end of the treatment period.
53. The use of claim 48, wherein the HCV RNA level is below the LLOQ 36 weeks after the end of the treatment period.
54. The use of claim 48, wherein the HCV RNA level is below the LLOQ 48 weeks after the end of the treatment period.
55. The use of claim 48, wherein the LLOQ is 25 IU / mL.
56. The use of claim 48, wherein the LLOQ is 15 IU / mL.
57. The use of claim 48, wherein the LLOQ is 12 IU / mL.
58. The use of claim 48, wherein the HCV RNA level is quantified using a real-time polymerase chain reaction based assay.
59. The use of any one of claims 11 to 14, wherein the DAA is administered daily.
60. The use of any one of claims 11 to 14, wherein the DAA is selected from a protease inhibitor, a nucleoside polymerase inhibitor, a nucleotide polymerase inhibitor, a non-nucleoside polymerase inhibitor, an NS3B inhibitor, an NS3 / 4A inhibitor, an NS4A inhibitor, an NS5A inhibitor, an NS5B inhibitor and a cyclophilin inhibitor.
61. The use of any one of claims 11 to 14, wherein the DAA is selected from one or more of the following: sofosbuvir, ledipasvir, ombitasvir, dasabuvir, gleprevir, pibrentasvir, ibasvir, grazoprevir, ribavirin, ombitasvir, paritaprevir, ritonavir, boceprevir, vanirepvir, asunaprevir, daclatasvir, simeprevir, mecitabine, tergobuvir, danoprevir, sovaraprevir, voxiprevir, velpatasvir and GSK2878175.
62. The use of any one of claims 11 to 14, wherein the at least one DAA comprises sofosbuvir.
63. The use of any one of claims 11 to 14, wherein the at least one DAA comprises ledipasvir and sofosbuvir.
64. The use of any one of claims 10 to 14, wherein the dose of the drug is less than or equal to 4.0 mg / kg, less than or equal to 3.5 mg / kg, less than or equal to 3.0 mg / kg, less than or equal to 2.5 mg / kg, less than or equal to 2.0 mg / kg, less than or equal to 1.5 mg / kg, less than or equal to 1.0 mg / kg or less than or equal to 0.5 mg / kg.
